
10.1002/hbm.23516 file

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Biomarkers, Designs, and Interpretations of Resting-State fMRI in Translational Pharmacological Research: A Review of State-of-the-Art, Challenges, and Opportunities for Studying Brain Chemistry


1McGill Centre for Integrative Neuroscience, Montreal Neurological Institute, McGill University, Montreal, Canada
2PERFORM Centre, Concordia University, Montreal, Canada
3Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands
4Institute of Psychology and Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands
5Oxford Centre for Functional MRI of the Brain, Oxford University, Oxford, United Kingdom
6Biospective Inc, Montreal, Quebec, Canada
7McLean Hospital, Belmont, Massachusetts
8Harvard Medical School, Boston, Massachusetts
9Center for Pain and the Brain, Harvard Medical School & Boston Children’s Hospital, Boston, Massachusetts
10Department of Anesthesiology, Leiden University Medical Centre, Leiden, The Netherlands
11McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
12Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom
13Centre for Human Drug Research, Leiden University Medical Centre, Leiden, The Netherlands

Contract grant sponsor: Research Fellowship from PERFORM Center, Concordia University, Montreal, QC, as well as partial support from the Ludmer Foundation and McGill Centre for Integrative Neuroscience (MCIN), McGill University, Montreal, QC; Contract grant number: NIDA R21 DA032257; Contract grant sponsor: The Netherlands Organization for Scientific Research (NOW); Contract grant number: VICI grant nr. 016.130.677

Conflict of interest: The authors do not declare any conflict of interest in conducting this survey.

J v G is the director of CNS drug research in Centre for Human Drug Research (CHDR).

A P Z, and A C E are both shareholders in Biospective Inc.

*Correspondence to: Najmeh Khalili-Mahani, MEng, PhD, NW 143, Montreal Neurological Institute, 3801 University Street, Montreal, QC, Canada. E-mail: Najmeh.khalilimahani@mcgill.ca
Received for publication 23 February 2016; Revised 21 November 2016; Accepted 4 January 2017.
DOI: 10.1002/hbm.23516
Published online 1 February 2017 in Wiley Online Library (wileyonlinelibrary.com).

© 2017 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
**INTRODUCTION**

To study the neurochemical substrates of the brain function is one of the most important aspects of understanding inter-individual variations in behavior or clinical outcomes of psychotherapeutic interventions. Direct evaluation of brain chemistry in vivo has been made possible by positron emission tomography (PET). In PET, the dynamics of the regional uptake of neurotransmitter-specific radioligands serve as evidence of the local neurochemical modulation of the brain activity. Generally, PET provides a quantifiable measure of glucose metabolism through the use of 18FDG, a direct reflection of regional glutamate transmission. When receptor-specific radioligands exist (e.g., 11C-CARFENTANYL and 11C-METHYLNALTRINDOLE for opioid; 11C-RACLOPRIDE, 18F-FALLYPRIDE for Dopamine R2; 11C-SCH39166, 11C-NNC-112 for Dopamine R1; 11C-WAY635 for serotonin 5HT1A; 11C-AZI0419369 for 5HT1B; 18F-SETOPERONE for 5HT2A; 18F-FLUMAZENIL for GABA, etc.), PET serves as the gold standard for studying brain chemistry. The neural correlates of anesthetics [Alkire et al., 1995], analgesics [Hartvig et al., 1995; Wagner et al., 2001], drug-induced psychosis [Lahti et al., 1995; Onoe et al., 1994; Vollenweider et al., 1997], depression [Fowler et al., 1987; Hartvig et al., 1995] or euphoric intoxication [Volkow et al., 1991, 1995] have long been investigated with this technology. However, PET is not an easy or cheap research tool. Appropriate ligands do not always exist, or if they do, facilities that can produce them are not accessible broadly. Even when the technology is accessible, experimental designs are constrained by the half-life of both the drug and the tracer isotope. The time-dependency of PET experiments can sometimes make them more difficult to conduct and analyze. Furthermore, the complex dynamics of drug actions on peripheral and autonomic autoregulation (which will be discussed in the following sections) increase the challenge of tracer kinetic modeling with respect to non-specific uptake within a so-called “reference region.” Importantly, dose-radiation restrictions make PET unsuitable for repeated crossover study designs in humans. In fact, some Ethics Research Boards restrict PET scans in healthy individuals. These practical considerations have shifted the spotlight onto pharmacological fMRI (pharma-fMRI) as an affordable exploratory option for accelerating bench-to-bed clinical research applications [Wise and Tracey, 2006].

MRI methods are not without challenge either. Earlier reviews have thoroughly covered the practical and theoretical challenges and promises of task-based pharma-fMRI [Borsook et al., 2008, 2011; Iannetti and Wise, 2007] and...
resting-state fMRI [Liu, 2013; Lu and Stein, 2014]. The most important limitation is that fMRI signals hinge on the assumption that neuronal metabolism and cerebral blood flow are proportionally related to electrophysiological activity of neurons—but these relations are far more complex than generally considered [Logothetis, 2008]. The question is whether existing RSfMRI studies of acute drug effects provide enough evidence to make this method a valid alternative to PET for studying the neurochemistry of the brain. We approached this question by surveying the state-of-the-art resting-state methods that have been used in pharmacological RSfMRI (Pharma-RSfMRI) studies of acute drug effects on the brain. The survey is organized in a manner to bridge between neuroimaging experts—who like to become familiar with analytical complexities that arise from neurochemical modulation of the brain—as well as clinical researchers who need noninvasive neuroimaging biomarkers in pharmacological or diagnostic applications. We focused on identifying challenges and opportunities in pharma-RSfMRI, and areas that need further development and testing.

This review includes (to the best of our knowledge) all pharma-RSfMRI in any PubMed publications listed between Jan 2000 and Jan 2016. Our search was limited to studies in which acute effects of drugs on resting-state brain function were investigated. For each of these 85 studies we have extracted information about experimental design, statistical modeling, acquisition parameters and subject demographics and clinical indications (Table I). Reports in which the latent drug effects are studied after a few days were excluded. We summarize acquisition and analytical methods used in these studies by providing examples of application, interpretation and limitations (“Basics and Biomarkers”); describe various experimental approaches that demonstrate the potential of pharma-RSfMRI in pharmacological, clinical and translational applications (“Experimental Objectives and Clinical Relevance”), and outline theoretical, practical and methodological factors that challenge current interpretations and demand further research (“Challenges and Limitations”). Finally, we propose a unifying framework that proposes standardizing design and multimodal data acquisition, as well as an integrative approach to data fusion and analytical approaches that will be important both for neuropharmacology, and basic and clinical research studies (“Opportunities and Future Directions”).

**Basics and Biomarkers**

Drugs modulate the neuronal and metabolic signals by acting on neurotransmitter receptors (directly or via indirect pathways). Figure 1A presents a schematic overview of the complex cascade of signaling pathways affected by different drugs. Drugs may act by directly targeting their receptors in the central or autonomic nervous systems. They can also act indirectly, by acting peripherally and causing sympathetic and parasympathetic responses related to adaptive feedback regulation. Together, this cascade of events translates to fast and slow alterations in mental and proprioceptive states, sending top-down and bottom-up signals between the central and autonomic nervous systems in order to adaptively regulate behavior and homeostasis. The fMRI technique measures changes in blood-oxygen-level dependent (BOLD) signal or blood flow and volume (CBF and CBV) in response to such cascade neuromodulation of the brain.

**Pharmacological fMRI (Pharma-fMRI)**

The overall goal of pharmacological fMRI is to identify the site of drug action fingerprinting to estimate the relation between drug-dose, brain response and clinical outcome over time (pharmacokinetic/pharmacodynamic modeling); and to help make go-no-go decisions about the efficacy of drug-treatment in clinical trials—aimed to accelerate the drug discovery process. Pharmacological probing experiments can also be important for basic neuroscience and validation studies, by allowing a controlled modulation of a specific pathway and studying its causal effect on other signals and systems. More on this is covered in “Experimental Objectives and Clinical Relevance.”

Initial pharma-fMRI experiments involved collecting regular task-fMRI data and either comparing the activation maps (i.e., % of the BOLD signal change in response to task) under drug (at one or more dose strengths) versus no-drug conditions, or estimating differences in the hemodynamic response functions between drug and control conditions (Fig. 1B). Task-based pharma-fMRI is valuable for hypothesis testing, but difficult to conduct in translational or large-scale clinical studies where standardization of tasks and normalization of performance metrics is virtually impossible (yet). Another important pharma-fMRI approach is to evaluate the pharmacodynamics of the brain response by collecting fMRI data continuously over the course of drug infusion, and then evaluating the percentage of signal change from the pre-drug baseline as a surrogate for drug-induced neuronal activation [e.g., Becerra et al, 2006; Bloom et al, 1999; De Simoni et al, 2013]. This method is suitable for studying fast-acting drugs or for anesthesiology experiments, where pharmacokinetic models help reach (pseudo)steady-state plasma drug concentrations over time (Fig. 1C). We refer to this technique as phfMRI. A more recent pharma-fMRI approach involves pharmacological “resting-state” fMRI (pharma-RSfMRI) in which spontaneous brain activity is recorded at several brief intervals over the course of drug administration, and the dynamics of change in spectral power or network properties of the brain are evaluated across different phases of the pharmacokinetic profile (Fig. 1D). This review excludes task pharma-fMRI studies, and focuses on measuring BOLD and CBF signals under resting-state.

More than 75% of studies surveyed here use T2*-weighted echo planar imaging (EPI) which is sensitive
<table>
<thead>
<tr>
<th>Drug</th>
<th>Objective</th>
<th>Mode of delivery</th>
<th>Dosage</th>
<th>PK</th>
<th>Placebo</th>
<th>Analytical approach</th>
<th>A Priori ROI</th>
<th># scans per subject</th>
<th>Statistical Design</th>
<th>Patient (N male / N female) (age range or mean/sd)</th>
<th>Healthy (N male / N female) (age range or mean/sd)</th>
<th>MRI parameters (Field, Sequence)</th>
<th>Physiological monitoring/Correction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>DR</td>
<td>IV</td>
<td>4 mg/70 kg morphine</td>
<td>X ✓</td>
<td>✓</td>
<td>% BOLD signal (PhMRI)</td>
<td></td>
<td>2</td>
<td>Mixed effect GLM (Morphine × time – Saline × time)</td>
<td>8/0 (28.3/2.86) cardiac cycles</td>
<td>N = 250</td>
<td>1.5T, T2* EPI (TR = 6 s)</td>
<td>✓/✓</td>
</tr>
<tr>
<td>Morphine</td>
<td>FP</td>
<td>Bolus + pseudosteady 14.5 mg/70 kg</td>
<td>✓ ✓</td>
<td>✓</td>
<td>✓</td>
<td>NOI + DR</td>
<td>Beckmann’s 8 RSN template</td>
<td>21</td>
<td>Mixed GLM Drug dose or dose (t – t0) – Placebo (t1 – t0)</td>
<td>12/0 (18–40)</td>
<td>3T, T2* EPI (TR = 2.2 s)</td>
<td>N = 220</td>
<td>✓/✓</td>
</tr>
<tr>
<td>Morphine</td>
<td>FP</td>
<td>Bolus + pseudosteady 14.5 mg/70 kg</td>
<td>✓ ✓</td>
<td>✓</td>
<td>✓</td>
<td>Global CBF, rCBF</td>
<td></td>
<td>6</td>
<td>Mixed GLM Drug dose or dose (t – t0) – Placebo (t1 – t0)</td>
<td>12/0 (18–40)</td>
<td>3T, PCASL, 30 pairs</td>
<td>✓/✓</td>
<td></td>
</tr>
<tr>
<td>Remifentanil</td>
<td>DR</td>
<td>IV</td>
<td>0.5 µg/kg 3 times 7 min each 0.5 µg/kg vs. 7 min saline</td>
<td>X X</td>
<td></td>
<td>Whole brain % BOLD signal change (PhMRI)</td>
<td>4</td>
<td>Fixed effect Mean (BOLDi – BOLDj) – Mean (BOLDi – BOLDj)</td>
<td>4/4 (22–28)</td>
<td>1.5T, T2* EPI (TR = 3 s)</td>
<td>N = 600</td>
<td>✓/x</td>
<td></td>
</tr>
<tr>
<td>Heroin</td>
<td>PR</td>
<td>IV (only in patients) Plasma Morphine lev- els (ng/mL at min 3, 10 and 60: 529 ± 726; 334 ± 136, and 224 ± 92)</td>
<td>X ✓</td>
<td></td>
<td></td>
<td>ICA + DR</td>
<td>Basal ganglia/limbic network</td>
<td>2</td>
<td>Placebo-Heroin (patients) Patients – Controls (Placebo)</td>
<td>14/6 (40/24/10:91)</td>
<td>3T, T2* EPI (TR = 2), N = 152</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Remifentanil</td>
<td>FP</td>
<td>Regular morning dose per subject</td>
<td>✓ ✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>CV/FP/DR</td>
<td>IV (Cohort 1 0.1 mg/70 kg Cohort 2 0.2 mg/70 kg) andSublingual (2.0 mg)</td>
<td>✓ ✓</td>
<td></td>
<td></td>
<td>Seed + PK/PD modeling</td>
<td>Putamen</td>
<td>1</td>
<td>Mixed Effect Paired comparison</td>
<td>36/0 (28.0/2.5)</td>
<td>3T, T2* EPI (TR = 2.5), N = 360</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>FP</td>
<td>Oral</td>
<td>0.5 g/L</td>
<td>X X</td>
<td>✓</td>
<td>ICA + DR</td>
<td>DMN, VIS, FPN</td>
<td>2</td>
<td>Paired t-test</td>
<td>8/7 (26/1.2)</td>
<td>1.5T, T2* EPI (TR = 2)</td>
<td>N = NA</td>
<td>X/X</td>
</tr>
<tr>
<td>Alcohol</td>
<td>FP</td>
<td>Oral</td>
<td>0.7 mL/kg</td>
<td>X X</td>
<td>✓</td>
<td>ICA</td>
<td>VIS, DMN, FPN, SMN, AUD and the self-referential (SRN)</td>
<td>4</td>
<td>2-factor ANOVA</td>
<td>5/3 (28/3.2)</td>
<td>3T, T2* EPI (TR = 1.5 s)</td>
<td>N = 240</td>
<td>✓/✓</td>
</tr>
<tr>
<td>Alcohol</td>
<td>FP</td>
<td>IV (clamping)</td>
<td>0.6 g/L</td>
<td>✓ ✓</td>
<td></td>
<td>NOI + DR</td>
<td>Beckmann’s 8 RSN template</td>
<td>21</td>
<td>Mixed GLM Drug dose or dose (t – t0) – Placebo (t1 – t0)</td>
<td>12/0 (18–40)</td>
<td>3T, T2* EPI (TR = 2.2 s)</td>
<td>N = 220</td>
<td>✓/✓</td>
</tr>
<tr>
<td>Alcohol</td>
<td>DR</td>
<td>IV</td>
<td>0.6 g/L</td>
<td>X ✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>DR</td>
<td>Oral</td>
<td>0.6 g/kg</td>
<td>✓ ✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>DR</td>
<td>Oral</td>
<td>0.6 g/kg</td>
<td>✓ ✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLE I.** List of reviewed studies and their experimental design and data acquisition parameters.
### TABLE I. (continued).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Objective</th>
<th>Mode of delivery</th>
<th>Dosage</th>
<th>PK</th>
<th>Placebo</th>
<th>Analytical approach</th>
<th>A Priori ROI</th>
<th># scans per subject</th>
<th>Statistical Design</th>
<th>Patient (N male / N female)</th>
<th>Healthy (N male / N female)</th>
<th>MRI parameters (Field, Sequence)</th>
<th>Physiological monitoring/Correction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>FP</td>
<td>Oral</td>
<td>0.6 g/kg</td>
<td></td>
<td></td>
<td>PWI, rCBF</td>
<td></td>
<td></td>
<td></td>
<td>10/9</td>
<td>3T, PASL, FAIR, QUIPS2</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>FP</td>
<td>IV (clamping)</td>
<td>0.6 g/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12/0</td>
<td>3T, FCASL, 30 Pairs</td>
<td>✓/✓</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>FP/CV</td>
<td>IV</td>
<td>1.2 µg/ml</td>
<td></td>
<td></td>
<td>ICA + Seed</td>
<td>VIS, DMN, AUD, SMN, Thalamus</td>
<td>1</td>
<td>Full factorial ANOVA (Network, Condition=awake vs. unconscious)</td>
<td>15/0 (25.8 + N.A)</td>
<td>3T, T²* EPI (TR = 1.8 s) N = 300</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>FP</td>
<td>IV</td>
<td>1.2 µg/ml</td>
<td></td>
<td></td>
<td>Graph theory</td>
<td>Thalamus, Pons, Brainstem</td>
<td>2</td>
<td>Permutation-based Paired t-test Eigenvector centrality (sedation vs. awake)</td>
<td>15/0 (20-41)</td>
<td>3T, T²* EPI (TR = 3 s) N = 160</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>PR</td>
<td>IV</td>
<td>1.71 µg/ml</td>
<td></td>
<td></td>
<td>ICA Seed</td>
<td>DMN and AUD, ACC, Thalamus, brainstem and Hippocampus</td>
<td>1</td>
<td>Average t-maps, Fingerprints and Connectivity graphs per state of consciousness (awake, mild, deep, recovery)</td>
<td>4/13 (21.9/1.9)</td>
<td>3T, T²* EPI (TR = 2.5 s) N = 235 ± 74</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>PR</td>
<td>IV</td>
<td>1.75 µg/ml</td>
<td></td>
<td></td>
<td>Seed</td>
<td>PCC (DMN), Middle Frontal gyrus (ECN)</td>
<td>1</td>
<td>ANOVA (DMN or ECN connectivity: Wakeful, mild, deep, recovery)</td>
<td>4/16 (22.4/3.4)</td>
<td>3T, T²* EPI (TR = 2.5 s) N = 196</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>CV</td>
<td>Same as [Boveroux et al., 2010]</td>
<td></td>
<td></td>
<td></td>
<td>Network hierarchy clustering</td>
<td></td>
<td>1</td>
<td>Same as [Boveroux et al., 2010]</td>
<td></td>
<td></td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>CV</td>
<td>IV (4.1 ± 0.9) mg</td>
<td>Tittered until Ramsay scale 3</td>
<td></td>
<td></td>
<td>ICA</td>
<td>DMN, SMN</td>
<td>1</td>
<td>Paired t-test (rest, sedation)</td>
<td>4/5 (22-27)</td>
<td>1.5T, T²* EPI (TR = 2 s) N = 82</td>
<td>✓/✓</td>
<td></td>
</tr>
<tr>
<td>Zolpidem</td>
<td>CL</td>
<td>Oral</td>
<td>10 mg</td>
<td></td>
<td></td>
<td>Hemodynamic modeling (PosMRI)</td>
<td>Left frontal cortex</td>
<td>4</td>
<td>%BOLD (post – pre) 0/1 brain injured (21)</td>
<td>Age matched control</td>
<td>1.5T, T²* EPI (TR = 3 s) N = 60</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Objective</td>
<td>Mode of delivery</td>
<td>Dosage</td>
<td>PK</td>
<td>Placebo</td>
<td>Analytical approach</td>
<td>A Priori ROI</td>
<td># scans per subject</td>
<td>Statistical Design</td>
<td>Patient (N male / N female) (age range or mean/sd)</td>
<td>MRI parameters (Field, Sequence)</td>
<td>Physiological monitoring/Correction</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------</td>
<td>------------------</td>
<td>--------</td>
<td>----</td>
<td>---------</td>
<td>--------------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------</td>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td>26 Zolpidem [Licata et al., 2013]</td>
<td>PR</td>
<td>Oral</td>
<td>0, 5, 10 or 20 mg</td>
<td>X ✓</td>
<td>ICA + DR</td>
<td>VIS, TEMP</td>
<td>VIS, TEMP</td>
<td></td>
<td>One-factor repeated measure ANOVA (0,5,10, 20 mg)</td>
<td>6/6 24.2/2.3</td>
<td>3T, T2* EPI (TR = 3 s) N = 200</td>
<td>✓/X</td>
<td></td>
</tr>
<tr>
<td>27 Benzodiazepine (GABA) [Flodin et al., 2012]</td>
<td>PR</td>
<td>Oral</td>
<td>Osazepam (20 mg)</td>
<td>X ✓</td>
<td>Seed,FAFF and REHO</td>
<td>DMN(PCC, vmPFC) PMN(M1, Put) Amyg, Primary visual and NAcc (area affected by PD)</td>
<td>DMN(PCC, vmPFC) PMN(M1, Put) Amyg, Primary visual and NAcc (area affected by PD)</td>
<td>1 2 Sample t-test (Osazepam – placebo)</td>
<td>9/11 (24.6/4.4) Osazepam 8/14 (25.5/4.6) Placebo</td>
<td>1.5T, T2* EPI (TR = 2.5 s) N = 192</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28 Dopamine [Flodin et al., 2012]</td>
<td>PR</td>
<td>Oral</td>
<td>Levodopa (100 mg)</td>
<td>X ✓</td>
<td>ICA + DR</td>
<td>VIS, DMN, SMN, EXEC, AUD, LVDS, RVDS,</td>
<td>VIS, DMN, SMN, EXEC, AUD, LVDS, RVDS,</td>
<td>1 2 Sample t-test (LDOPA – placebo)</td>
<td>10/9 (22.3/3.3) Levodopa 10/10F (22.8/4.5) placebo</td>
<td>8/14 (25.5/4.6) Placebo</td>
<td>3T, T2* EPI (TR = 2.2 s) N = 220</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>29 Dopamine [Cole et al., 2013]</td>
<td>PR</td>
<td>Oral</td>
<td>Haloperidol (3 mg) Levodopa (100 mg) Carbidopa (25 mg)</td>
<td>1 1 2 Sample t-test (Levodopa – placebo)</td>
<td>16/0 (23.4/5.3) 15/0 (21.5/3) Placebo</td>
<td>1 Two-sample t-test (Levodopa – placebo)</td>
<td>1 Two-sample t-test (Levodopa – placebo)</td>
<td>1 Two-sample t-test (Haloperidol – placebo)</td>
<td>18/0 (22.2/3.3) Levodopa 10/10F (22.8/4.5) placebo</td>
<td>1 Two-sample t-test (Haloperidol – placebo)</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 Dopamine [Esposito et al., 2013]</td>
<td>PR/CL</td>
<td>Oral</td>
<td>Levodopa/carbofoduca (250/25 mg) Placebo</td>
<td>X ✓</td>
<td>ICA and FAFF</td>
<td>SMN, DMN, Basal Ganglia</td>
<td>SMN, DMN, Basal Ganglia</td>
<td>2 PD 1 HC Two-sample t-tests and two-way ANOVA interaction model</td>
<td>Drug-naive PD 5/5 (60.8/2.7) Placebo 5/5 (66/1.7)</td>
<td>10/8 59.2/1.52</td>
<td>3T, T2* EPI (TR = 1.5 s) N = 240</td>
<td>✓/✓</td>
<td></td>
</tr>
<tr>
<td>31 Dopamine [Carbonelli et al., 2014]</td>
<td>PR</td>
<td>Oral</td>
<td>nutritionally balanced 100 g amino acid mixture (BAL), and tyrosine and phe- nylalanine deficient (APTD)</td>
<td>X ✓</td>
<td>Graph analysis Modularity</td>
<td></td>
<td></td>
<td></td>
<td>Mixed-effects GLM (f- test BAL vs. APTD) + covariance of no interest (sex and age),</td>
<td>11/6 (23.6/4.4)</td>
<td>3T, T2* EPI (TR = 2.04 s) N = 180</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>32 Dopamine [Vytlacil et al., 2014]</td>
<td>PR</td>
<td>Oral</td>
<td>1.25 mg Bromocriptine (DA)</td>
<td>X ✓</td>
<td>Seed</td>
<td>Bilateral caudate, putamen and ventral striatum, brainstem</td>
<td></td>
<td></td>
<td>2 2 × 2 ANOVA with factors of drug (bromocriptine vs placebo) and span (high vs low)</td>
<td>8/0 (18–22)</td>
<td>3T, T2* EPI (TR = 2 s) N = NA</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>33 Dopamine [Kelly et al., 2009]</td>
<td>PR</td>
<td>Oral</td>
<td>Levodopa 100 mg (25 mg of benserazide)</td>
<td>X ✓</td>
<td>Seed (multiple regression)</td>
<td>inferior ventral striatum, superi- or ventral striatum, dorsal caudate and putamen</td>
<td></td>
<td></td>
<td></td>
<td>Repeated-measures mixed-effects (Drug vs placebo)</td>
<td>12/7 (26.2/NA)</td>
<td>4T, T2* EPI (TR = 2.1 s) N = 200</td>
<td>X/X</td>
</tr>
<tr>
<td>34 Dopamine [Fernandez-Seara et al., 2011]</td>
<td>DR</td>
<td>Oral</td>
<td>10 mg metoclopra- mid (DA)</td>
<td>X ✓</td>
<td>CBF, rCBF and seed</td>
<td>- Haemodynamics in ventral and internal carotid arteries with phase contrast MRI - putamen and insula</td>
<td></td>
<td></td>
<td>2 × 2 repeated measures ANOVA factors treatment (metoclo- pramide, placebo) and session (baseline, post-medication)</td>
<td>8/10 (23.9/4.5)</td>
<td>3T, PCASL, 50 pairs</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Objective</td>
<td>Mode of delivery</td>
<td>Dosage</td>
<td>PK</td>
<td>Placebo</td>
<td>Analytical approach</td>
<td>A Priori ROI</td>
<td># scans per subject</td>
<td>Statistical Design</td>
<td>Patient (N male / N female) (age range or mean/SD)</td>
<td>Healthy (N male / N female) (age range or mean/SD)</td>
<td>MRI parameters (Field, Sequence)</td>
<td>Physiological monitoring/ Correction</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>----</td>
<td>---------</td>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------</td>
<td>----------------------------------</td>
<td>--------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>35 Cocaine</td>
<td>[Kaufad et al., 2005]</td>
<td>DR</td>
<td>IV (40 mg/70 kg)</td>
<td>✓</td>
<td>✓</td>
<td>%BOLD (PhMRI)</td>
<td>- Amygdala, PFC, Nacc</td>
<td>2</td>
<td>Single-subject cocaine vs saline Group: Correlation with craving scores</td>
<td>8/7 (N/a) Cocain abuser &gt;6 years</td>
<td>1.5T, EPI (MultiEcho Segmented EPI with z-shimmmed BAcground gradient Compensation (MEBAC))</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>36 Methylenphenidate</td>
<td>[Koneva et al., 2013]</td>
<td>PR</td>
<td>Oral 20 mg</td>
<td>X</td>
<td>✓</td>
<td>Seed</td>
<td>VTA, Nacc, amygadla hippocampus, thalamus, rACC</td>
<td>4</td>
<td>t-test: Post-drug ~ baseline drug, t-test: baseline ~ placebo</td>
<td>16/2F (45/17) cocain addicts</td>
<td>4T, T2* EPI (TR = 1.6 s) N = 320</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>37 Methylenphenidate</td>
<td>[Ramaekers et al., 2013]</td>
<td>PR</td>
<td>Oral 40 mg</td>
<td>X</td>
<td>✓</td>
<td>Seed</td>
<td>NAcc and medial dorsal nucleus</td>
<td>2</td>
<td>Paired t-test (Drug – Placebo)</td>
<td>9/11 (23-35)</td>
<td>3T, T2* EPI (TR = 2 s) N = 192</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>38 Methylenphenidate</td>
<td>[An et al., 2013]</td>
<td>CL</td>
<td>Oral 10 mg</td>
<td>X</td>
<td>✓</td>
<td>REHO</td>
<td>2 × 2 repeated measure ANOVA factors illness (CUD vs. HC) and drug (MPH vs. placebo)</td>
<td>2</td>
<td>Unpaired t-test: ADHD drug ~ ADHD placebo, Paired t-test: ADHD drug ~ ADHD placebo</td>
<td>23 M (12.5 ± 1.8) ADHD</td>
<td>3T, T2* EPI (TR = 2 s) N = NA</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>39 Methylenphenidate</td>
<td>[Koneva et al., 2015]</td>
<td>CL</td>
<td>Oral 20 mg</td>
<td>✓</td>
<td>✓</td>
<td>Global Connectivity</td>
<td>2 × 2 repeated measure ANOVA factors illness (CUD vs. HC) and drug (MPH vs. placebo)</td>
<td>2</td>
<td>Paired t-test drug vs. placebo</td>
<td>54/0 (23.65/2.97)</td>
<td>3T, T2* EPI (TR = 3 s) N = 120</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>40 Methylenphenidate</td>
<td>[Mueller et al., 2014]</td>
<td>FP</td>
<td>Oral 40 mg</td>
<td>X</td>
<td>✓</td>
<td>ICA + DR</td>
<td>DMN, ECN, FPN, SMN, VIS, DAN</td>
<td>2</td>
<td>Paired t-test drug vs. placebo</td>
<td>16/16 (20.6/2.0)</td>
<td>3T, T2* EPI (TR = 2 s) N = 180</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>41 Methylenphenidate</td>
<td>[Sripada et al., 2013b]</td>
<td>FP</td>
<td>Oral 40 mg</td>
<td>X</td>
<td>✓</td>
<td>SVM</td>
<td>2 × 2 repeated measure ANOVA factors illness (CUD vs. HC) and drug (MPH vs. placebo)</td>
<td>2</td>
<td>Paired t-test drug vs. placebo</td>
<td>54/0 (23.65/2.97)</td>
<td>3T, T2* EPI (TR = 3 s) N = 120</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>42 Modafinil</td>
<td>[Schaal et al., 2013]</td>
<td>CL</td>
<td>Oral 200 mg</td>
<td>X</td>
<td>✓</td>
<td>ICA</td>
<td>DMN, Salience, Executive</td>
<td>2</td>
<td>Paired t-test (THC – Placebo) (b0 + t0)</td>
<td>6/0 Alcohol (43/2.4)</td>
<td>3T, T2* EPI (TR = 2.3 s) N = 200</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>43 Modafinil</td>
<td>[Esposito et al., 2013b]</td>
<td>FP</td>
<td>Oral 100 mg</td>
<td>X</td>
<td>✓</td>
<td>ICA</td>
<td>DMN, ECN, FPN, SMN, VIS, DAN</td>
<td>2</td>
<td>Three way mixed design ANOVA (Group × time × treatment)</td>
<td>13/0 (23-35)</td>
<td>3T, T2* EPI (TR = 1.67 s) N = 140</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>44 Cannabis</td>
<td>[Klumpers et al., 2012]</td>
<td>FP</td>
<td>THC inhalation 2, 6, 6 mg</td>
<td>✓</td>
<td>✓</td>
<td>NOI + DR</td>
<td>Beckman &amp;r’s 8 RSN template</td>
<td>16</td>
<td>Mixed GLM Drug dose = (a0 + t0 – t) – Placebo(b0 + t0)</td>
<td>9/3 (22/2.25)</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45 Cannabis</td>
<td>[Van Hell et al., 2011]</td>
<td>FP</td>
<td>THC inhalation 6 mg + 1 m updosed every 30 min</td>
<td>X</td>
<td>✓</td>
<td>temporal signal-to-noise ratio</td>
<td>2 Paired t-test (THC – Placebo) (b0 + t0)</td>
<td>2</td>
<td>Paired t-test (THC – Placebo) (b0 + t0)</td>
<td>20/0 (21.1/2.1)</td>
<td>3T, T2*, SENSE-PRESTO (TR = 0.0225 s), N = 400</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>46 Cannabis</td>
<td>[Van Hell et al., 2011]</td>
<td>FP</td>
<td>Same as above</td>
<td>X</td>
<td>✓</td>
<td>Global CBF, rCBF</td>
<td>2 Paired t-test (THC – Placebo) (b0 + t0)</td>
<td>20/0 (21.1/2.1)</td>
<td>3T, PCASL, 30 pairs</td>
<td>X/X</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Objective</td>
<td>Mode of delivery</td>
<td>Dosage</td>
<td>PK</td>
<td>Placebo</td>
<td>Analytical approach</td>
<td>A Priori ROI</td>
<td># scans per subject</td>
<td>Statistical Design</td>
<td>Patient (N male / N female) (age mean/sd)</td>
<td>Healthy (N male / N female) (age range or mean/sd)</td>
<td>MRI parameters (Field, Sequence)</td>
<td>Physiological monitoring / Correction</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----------------</td>
<td>--------</td>
<td>----</td>
<td>---------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>47</td>
<td>Insulin</td>
<td>PR</td>
<td>Intranasal solution 40 IU insulin (400 IU/mL) × 4 times</td>
<td>X</td>
<td>✓</td>
<td>fALFF</td>
<td></td>
<td>6</td>
<td>Mixed GLM Insulin (post 1 and 2 – placebo) (post 1 and 2 – placebo)</td>
<td>0/17 (24.5/2.2)</td>
<td>3T, T2*, EPI (TR = 1.8 s) N = 320</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Sucrose</td>
<td>PR</td>
<td>Oral (50 g truvia, low calorie) vs. (50 g sugar, high calorie)</td>
<td>X</td>
<td>✓</td>
<td>Seed + fALFF</td>
<td>Hypothalamus and brainstem</td>
<td>2</td>
<td>3-way ANOVA (Group, Treatment, Time)</td>
<td>0/11 healthy obese (27/1.9)</td>
<td>1.5T, T2* EPI (TR = 2 s) N = NA</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Exenatide</td>
<td>PR</td>
<td>0.12 pmol/kg/min target 0.1-0.2 mg/L</td>
<td>✓</td>
<td>✓</td>
<td>Graph Theory</td>
<td>Hypothalamus</td>
<td>2</td>
<td>Paired t-test: drug – placebo</td>
<td>24M (obese) (29/7)</td>
<td>3T, T2* EPI (TR = 2 s) N = NA</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Ketamine</td>
<td>PR/DR/FP</td>
<td>Experiment 1: IV ketamine bolus 0.26 mg/kg plus 0.25 mg/kg/h</td>
<td>✓</td>
<td>✓</td>
<td>%BOLD signal</td>
<td>PCC (DMN)sgACC, Affective network</td>
<td>2</td>
<td>One-way ANOVA on 8 blocks of %BOLD signal change (activation maps)</td>
<td>12/0 (22.2/3.85)</td>
<td>1.5T, T2* EPI (TR = 3 s) N = NA</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Ketamine and Lamotrigine</td>
<td>PR/DR/FP</td>
<td>Experiment 2: IV Ketamine: Bolus 0.26 mg/kg plus 0.25 mg/kg/h Oral Lamotrigine 300 mg</td>
<td>✓</td>
<td>✓</td>
<td>Seed DLPFC (cognitive control network)</td>
<td>PCC (DMN)sgACC, Affective network</td>
<td>2</td>
<td>Paired-t-test: baseline – follow-up</td>
<td>19/7 (40.5/7.5)</td>
<td>3T, T2* EPI (TR = 3 s) N = 200</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Ketamine</td>
<td>FP</td>
<td>IV 0.25 mg/kg</td>
<td>✓</td>
<td>✓</td>
<td>Seed</td>
<td>DLPC (cognitive control network)</td>
<td>4</td>
<td>Paired-t-test: baseline – follow-up</td>
<td>19/7 (40.5/7.5)</td>
<td>3T, T2* EPI (TR = 3 s) N = 200</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Ketamine</td>
<td>CV/DR</td>
<td>Same dose in two occasions 50 nmol/kg (5 subjects) and 75 nmol/kg (5 subjects)</td>
<td>✓</td>
<td>X</td>
<td>ICC GLM BOLD</td>
<td>Whole brain and ROI (ACC, PCC, Thalamus)</td>
<td>2</td>
<td>GLM with Gamma Variate model, shape capture, nuisance factors</td>
<td>10/0 (25.5 ± 6.5)</td>
<td>3T, T2* EPI (TR = 2 s) N = 400</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Ketamine, Lamotrigine, Risperidone</td>
<td>PR/DR/CV</td>
<td>IV Ketamine: 0.12 mh/kg bolus + 0.31 mk/h per hour Oral Lamotrigine 300 mg Oral Risperidone 2 mg</td>
<td>✓</td>
<td>✓</td>
<td>%BOLD signal Gaussian process classification</td>
<td></td>
<td>3</td>
<td>Least-square mean difference PLA-KET, LAM-KET, RIS-KET, PLA-SAL in “activated” regions</td>
<td>16/0 (25.8/5.7)</td>
<td>3T, T2* EPI (TR = 2 s) N = 450</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Ketamine</td>
<td>PR</td>
<td>0.23 mg/kg bolus and 0.30 mg/kg/h</td>
<td>✓</td>
<td>X</td>
<td>Global brain connectivity (GBC)</td>
<td></td>
<td>1</td>
<td>SPM: regional correlation of GBC with symptoms (PANSS factor scores)</td>
<td>14/8 (22–45)</td>
<td>3T, T2* EPI (TR = 1.5 s) N = 160</td>
<td>✓/X</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Ketamine</td>
<td>FP/DR</td>
<td>IV (20 mg/70 kg/h) for 1 h, followed by (40 mg/70 kg/h) for another hour</td>
<td>✓</td>
<td>✓</td>
<td>NOI/DR Beckmann’s 8 RSN template</td>
<td></td>
<td>5</td>
<td>Mixed GLM Drug (t1–t3) = Placebot (t1–t3) = Placebot</td>
<td>12/0 (19–36)</td>
<td>3T, T2* EPI (TR = 2.18 s) N = 220</td>
<td>✓/X</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Objective</td>
<td>Mode of delivery</td>
<td>Dosage</td>
<td>PK</td>
<td>Placebo</td>
<td>Analytical approach</td>
<td>A Priori ROI</td>
<td># scans per subject</td>
<td>Statistical Design</td>
<td>Patient (N male / N female) (age mean/sd)</td>
<td>MRI parameters (Field, Sequence)</td>
<td>Physiological monitoring/Correction</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----------------</td>
<td>--------</td>
<td>----</td>
<td>---------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Ketamine</td>
<td>PR</td>
<td>Same as [Niesters et al., 2012]</td>
<td>✓</td>
<td>✓</td>
<td>Seed</td>
<td>Hippocampus</td>
<td>10</td>
<td>Mixed GLM Drug (t1 – t4) – Placebo (t1 – t4) + cortisol</td>
<td>✓✓</td>
<td>12/0 (19–36)</td>
<td>3T, T2* EPI (TR = 2.18 s) N = 220</td>
<td>✓/X</td>
</tr>
<tr>
<td></td>
<td>[Khalili-Mahani et al., 2015]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CBF, rCBF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Ketamine and scopolamine</td>
<td>PR</td>
<td>IC Ketamine (0.5 mg/kg) Scopolamine (4 µg/kg)</td>
<td>✓</td>
<td>✓</td>
<td>Seed</td>
<td>Prelimbic cortex</td>
<td>3</td>
<td>T-test Drug – Placebo</td>
<td>12/12 (25)</td>
<td>3T, T2* EPI (TR = 1.79) N = 332</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Grimm et al., 2015]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Psilocybin</td>
<td>FP/PR</td>
<td>IV</td>
<td>2 mg</td>
<td>X</td>
<td>✓</td>
<td>%BOLD signal</td>
<td>MPFC</td>
<td>2</td>
<td>Mixed effect GLM drug related varia- tions in % BOLD sig- nal Mixed effect (drug – placebo)</td>
<td>13/2 (32/8.9)</td>
<td>3T, T2* EPI (TR = 3 s) N = 240</td>
<td>✓/✓</td>
</tr>
<tr>
<td></td>
<td>[Carhart-Harris et al., 2012]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(PhMRI)</td>
<td>Seed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>MDMA</td>
<td>FP/PR</td>
<td>Oral</td>
<td>100 mg</td>
<td>X</td>
<td>✓</td>
<td>Seed</td>
<td>vmPFC, Amygdala, Hippocampus</td>
<td>4</td>
<td>Mixed effect least square (Drug – Placebo)</td>
<td>18/7 (34/11)</td>
<td>3T, T2* EPI (TR = 3 s) N = 240</td>
<td>X/X</td>
</tr>
<tr>
<td></td>
<td>[Carhart-Harris et al., 2015]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Psilocybin and MDMA</td>
<td>FP</td>
<td>As [Carhart-Harris et al., 2013] and [Carhart-Harris et al., 2012]</td>
<td>X</td>
<td>✓</td>
<td>NOI + DR</td>
<td>20 Smith’s networks</td>
<td>Paired t-test (drug – placebo)</td>
<td>As above</td>
<td>3T, T2* EPI (TR = 3 s) N = 240</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Roseman et al., 2014]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Aripiprazole and Haloperidol</td>
<td>FP</td>
<td>Oral Haloperidol 3 mg Aripiprazole 10 mg</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
<td>NOI + DR</td>
<td>20 Smith’s networks</td>
<td>Paired t-test (drug – placebo)</td>
<td>As above</td>
<td>3T, T2* EPI (TR = 3 s) N = 240</td>
<td>X/X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Handley et al., 2013]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>Sertraline</td>
<td>FP</td>
<td>Oral</td>
<td>75 mg</td>
<td>✓</td>
<td>✓</td>
<td>NOI + DR</td>
<td>10 Smith’s 2009 networks</td>
<td>10</td>
<td>Mixed GLM Drug (t1 – t4) – Placebo (t1 – t4) + cortisol</td>
<td>6/6 (21/3)</td>
<td>3T, t2* EPI (TR = 2.2) N = 220</td>
<td>✓/✓</td>
</tr>
<tr>
<td></td>
<td>[Klaassen et al., 2015]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>Nicotine</td>
<td>DR</td>
<td>IV</td>
<td>1.5 mg</td>
<td>✓</td>
<td>✓</td>
<td>%BOLD (PhMRI)</td>
<td></td>
<td>1</td>
<td>PK model fitting, individual response 15 (F/M7) (26 smokers)</td>
<td>1.5T, T2* EPI (TR = 6 s), TE = 40</td>
<td>✓/✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Stein et al, 1998]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>Nicotine</td>
<td>FP</td>
<td>Patch</td>
<td>7 mg</td>
<td>X</td>
<td>✓</td>
<td>Global/local efficiency Wavelet</td>
<td>Limbic and para-limbic regions</td>
<td>4</td>
<td>2-way repeated measures ANOVA (Drug, Time)</td>
<td>9/6 (29.4/7.5)</td>
<td>3T, T2* EPI (TR = 2 s) N = NA</td>
<td>✓/✓</td>
</tr>
<tr>
<td></td>
<td>[Wylde et al., 2012]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>Nicotine</td>
<td>PR</td>
<td>Patch</td>
<td>7 mg</td>
<td>X</td>
<td>✓</td>
<td>ICA Spectral analysis</td>
<td>DMN and CCN</td>
<td>4</td>
<td>2-way repeated measures ANOVA (Drug, Time)</td>
<td>19/0 (30/9)</td>
<td>3T, T2* EPI (TR = 2 s) N = NA</td>
<td>✓/✓</td>
</tr>
<tr>
<td></td>
<td>[Tanabe et al., 2011]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>Acetazolamide</td>
<td>CV</td>
<td>IV</td>
<td>Bolus 14 mg/kg (max dose 1,200 mg)</td>
<td>X</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
<td>Global CBF, ACBF(post – pre)</td>
<td>1</td>
<td>Paired t-test ACBF</td>
<td>12/4 (56.3/ 13.8)</td>
<td>3T PCASL, 30 pairs</td>
</tr>
<tr>
<td>Drug</td>
<td>Objective</td>
<td>Mode of delivery</td>
<td>Dosage</td>
<td>PK</td>
<td>Placebo</td>
<td>Analytical approach</td>
<td>A Priori ROI</td>
<td># scans per subject</td>
<td>Statistical Design</td>
<td>Patient (N male / N female) (age mean/sd)</td>
<td>Healthy (N male / N female) (age range or mean/sd)</td>
<td>MRI parameters (Field, Sequence)</td>
<td>Physiological monitoring/Correction</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------</td>
<td>------------------</td>
<td>--------</td>
<td>----</td>
<td>---------</td>
<td>---------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>--------------------</td>
<td>------------------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>68 Scopolamine [Suckling et al., 2008]</td>
<td>CV</td>
<td>Subcutaneous scopolamine hydrochloride 0.3 mg (0.75 mL)</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>Estimation of the Hurst exponent (spectral power)</td>
<td>2</td>
<td>Mixed effect repeated measures ANOVA (age, drug)</td>
<td>5/6 (20-25) 5/6 (60-70)</td>
<td>3T, T2* EPI (TR = 1.1 s) N = 450 X</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69 Caffeine [Rack-Gomer et al., 2009]</td>
<td>PR/CV</td>
<td>Oral pill 200 mg</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>CBF, rCBF Motor Cortex (obtained from task-activation)</td>
<td>4</td>
<td>2-way repeated measures ANOVA (Drug, time)</td>
<td>4/5 (23-41)</td>
<td>3T, pASL, PI/CR/ QUIPSS2 ✓</td>
<td>✓/✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70 Caffeine [Rack-Gomer and Liu 2012]</td>
<td></td>
<td>Same as [Rack-Gomer et al., 2009]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5/4 (23-41)</td>
<td>3T, T2* EPI (TR = 1.8 s) N = NA ✓/✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>68 Caffeine [Wong et al., 2012]</td>
<td>CV</td>
<td>Oral pill 200 mg</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>CBF BOLD amplitude DMN and TPN</td>
<td>4</td>
<td>2-way repeated measures ANOVA (Drug, time)</td>
<td>4/6 (25/6)</td>
<td>3T, PCASL (GE), Pairs NA ✓/✓</td>
<td>✓/✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>72 Caffeine [Tal et al., 2013]</td>
<td>CV</td>
<td>[Wong et al., 2012]</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>BOLD amplitude and MIG</td>
<td>4</td>
<td></td>
<td></td>
<td>4/6 (25/6)</td>
<td>3T, T2* EPI (TR = 2 s) N = NA ✓/✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73 Oxytocin [Sripada et al., 2013a]</td>
<td>PR</td>
<td>Intranasal spray 40.32 mg (three puffs of 4 IU or 6.72 mg per nostril)</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>Seed Amygdala</td>
<td>2</td>
<td>Paired t-test drug – placebo</td>
<td>15/0 (30.7/10.2)</td>
<td>3T, T2* EPI (TR = 2 s) N = 100 X</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74 Oxytocin [Daddia et al., 2014]</td>
<td>PR/CL</td>
<td>Intranasal spray (three puffs of 4 IU or 6.72 mg per nostril) 40.32 mg</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>Seed Amygdala</td>
<td>2</td>
<td>Repeated measures ANOVA (Group, treatment)</td>
<td>18/0 (24/10.2)</td>
<td>3T, T2* EPI (TR = 2 s) N = NA ✓/✓</td>
<td>✓/✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75 Oxytocin [Paloyelis et al., 2016]</td>
<td>FP</td>
<td>Intranasal spray One puff (4 IU) of IN-OT (or placebo) every 30 s, alternating b/w nostrils 40 mg.</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>Global CBF, rCBF Pattern recognition</td>
<td>4</td>
<td>Flexible factorial model, ANOVA (treatment × time)</td>
<td>16/0 (25.8/4.4)</td>
<td>3T, PCASL (GE), Pairs NA ✓/✓</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76 Oxytocin [Freilinger et al., 2015]</td>
<td>PR</td>
<td>Intranasal spray Five puff (4 IU) of IN-OT in each nostril every 30 s (total 40 IU)</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>Seed Amygdala, MPFC, insula, dACC</td>
<td>1</td>
<td>Between group analysis Oxytocin vs Saline</td>
<td>20/20 (10.3/2.6)</td>
<td>3T, T2* EPI (TR = 2.3) N = NA ✓/✓</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>77 Oxytocin [Koch et al., 2015]</td>
<td>PR/CL</td>
<td>Intranasal spray Five puff (4 IU) of IN-OT in each nostril every 30 s (total 40 IU)</td>
<td>X ✓</td>
<td></td>
<td>✓</td>
<td>Seed Amygdala, MPFC, insula, dACC</td>
<td>2</td>
<td>ANOVA (Drug × Sex × Group)</td>
<td>20/21 (28/11)</td>
<td>3T, T2* EPI (TR = 2) N = 238 X</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>78 Chloral Hydrate [Wei et al., 2013]</td>
<td>PR</td>
<td>Oral 50 mg/kg Sedation score 5 (sleep)</td>
<td>X X</td>
<td></td>
<td></td>
<td>Local/global network efficiency, between centrality</td>
<td>1</td>
<td>Paired t-test (sedation – awake)</td>
<td>20/8 (10.3/2.6)</td>
<td>1.5T, T2* EPI (TR = 2 s) N = 180 X</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>79 Sevoflurane [Pelther et al., 2005]</td>
<td>PR</td>
<td>Intranasal 0%, 2.0% and 1.0% end-tidal sevoflurane ✓</td>
<td>X X</td>
<td></td>
<td>✓</td>
<td>Seed Primary motor M1</td>
<td>1</td>
<td># of connected vessels per state per subject</td>
<td>6/0 (22-24)</td>
<td>3T, T2* EPI (TR = 0.75 s) N = 280 ✓/✓</td>
<td>✓/✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Objective</td>
<td>Mode of delivery</td>
<td>Dosage</td>
<td>PK</td>
<td>Placebo</td>
<td>Analytical approach</td>
<td>A Priori ROI</td>
<td># scans per subject</td>
<td>Statistical Design</td>
<td>Patient (N male / N female) (age mean/sd)</td>
<td>Healthy (N male / N female) (age range or mean/sd)</td>
<td>MRI parameters (Field, Sequence)</td>
<td>Physiological monitoring/Correction</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>------------------</td>
<td>--------</td>
<td>----</td>
<td>---------</td>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>CV</td>
<td>0.25 MAC</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>BOLD/rCBF coupling</td>
<td>Anterior cingulate, Posterior cingulate, intraparietal lobule</td>
<td>1</td>
<td>Paired t-test: Perfusion (Blocks 2.4) – Perfusionno-anesthesia (Blocks 1,3,5) BOLDno-anesthesia (Blocks 2.4) – BOLDno-anesthesia (Blocks 1,3,5)</td>
<td>22 (19–30)</td>
<td>3T, pASL, STAR QUIPSS, interleaved BOLD (TR = 3 s)/ASL (TI = 700), fast suppression and phase correction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiopental</td>
<td>CV</td>
<td>IV 3 mg/kg/h</td>
<td>✓</td>
<td>X</td>
<td></td>
<td>Spectral analysis</td>
<td>Visual cortex seed</td>
<td>1</td>
<td>Individual</td>
<td>12 children various illness</td>
<td>1.5 T, TR = 3 N = NA</td>
<td>✓/X</td>
<td></td>
</tr>
<tr>
<td>Thiopental</td>
<td>CV</td>
<td>IV 6 mg/kg/h</td>
<td>x</td>
<td>✓</td>
<td></td>
<td>Spectral, ICA</td>
<td>VIS, AUD, SMN and blood vessel related component</td>
<td>1</td>
<td>12/0 (2–9.5)</td>
<td>1.5 T, TR = 2 N = 84</td>
<td>X/X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupivacaine</td>
<td>FP/PR/DR</td>
<td>Spinal tap Lumbar 3–4</td>
<td>x</td>
<td>✓</td>
<td></td>
<td>NOI, Seed</td>
<td>8 Beckmann’s NOIs Thalamic subsegments (Oxford) Insula</td>
<td>6</td>
<td>Mixed GLM Drug (t1/2 – t0) – Placebo (t1/2 – t0) + Pain</td>
<td>12/0 (23.7/3.4)</td>
<td>3T, T2* EPI (TR = 2.18) N = 220</td>
<td>✓/X</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>PR</td>
<td>Oral 10 mg</td>
<td>X</td>
<td>✓</td>
<td></td>
<td>Seed</td>
<td>Amygdala</td>
<td>1</td>
<td>Independent t-test (Cort – Placebo)</td>
<td>23/0 CORT 20/0 PLACEBO (19–28)</td>
<td>1.5T, T2* EPI (TR = 2.4) N = 265</td>
<td>✓/X</td>
<td></td>
</tr>
<tr>
<td>Steroids</td>
<td>PR</td>
<td>Oral 400 mg pregrenolone 400 mg DHEA Placebo</td>
<td>X</td>
<td>✓</td>
<td></td>
<td>Seed</td>
<td>Amygdala</td>
<td>1</td>
<td>Random effect 1-sample and 2-sample t-test</td>
<td>16/0pregn. 14/0 DHEA 15/0 Placebo (22.6/3.6)</td>
<td>3T, T2* EPI (TR = 2.4) N = 240</td>
<td>X/X</td>
<td></td>
</tr>
</tbody>
</table>

FP, finger printing; DR, dose response; CL, clinical; CV, calibration validation; PR, probing; DMN, default mode network; ECN, executive control network; VIS, visual network; AUD, auditory network; CCN, cognitive control network; SMN, sensorimotor network; FPN, frontoparietal network; DAN, dorsal attention network; TPN, temporoparietal network.
to BOLD contrast. T2*-weighted signals reflect NMR signal decay arising from local field inhomogeneities related to deoxygenation of hemoglobin—a proxy for neuronal activation resulting from increased oxidative metabolism. Oxygen metabolism is coupled to a hemodynamic response in order to deliver additional blood to the tissue, thus the BOLD signal summarizes the combined effects of vascular response, oxygen metabolism and cerebral perfusion. Around 14% of the studies that we have reviewed employed phfMRI and fit a model of the plasma drug concentration to the BOLD signal, and the rest used multiple metrics derived from RSfMRI measurements. The other 25% used different versions of the arterial spin labeling (ASL) techniques, which are sensitive to cerebral blood flow (CBF) (Fig. 2).

(A) Schematic diagram of the cascade of drug interactions that give rise to the hemodynamic response measured by fMRI (PNS, peripheral nervous system; ANS, autonomic nervous system, CNS, central nervous system). (B) Schematic diagram of possible pharmacological fMRI experiments. Top, task-based or calibrated fMRI in which drugs modulate the magnitude of stimulus versus no-stimulus signal; Middle, PhfMRI where the drugs cause a latent neurovascular response consistent with the pharmacokinetic profile of the drug; Below, repeated measurements of RSfMRI signal which will be used to derive connectivity or spectral metrics and study their dynamics over the pharmacodynamic profile. The red line shows the pharmacodynamic model of a drug (morphine). [Color figure can be viewed at wileyonlinelibrary.com]

**Spontaneous BOLD Signal Fluctuations and Functional Networks**

In RSfMRI, slow fluctuations in the BOLD signal (around 0.1 Hz frequency) serve as a proxy to regional spontaneous neuronal activity. Since the discovery of correlated patterns of BOLD signal fluctuations in the contralateral part of the un-stimulated motor cortex [Biswal, et al., 2005], RSfMRI has been explored to evaluate networks that are active in the brain at “rest” [Beckmann et al., 2005; Damoiseaux et al., 2006; Smith et al., 2012] and to compare these resting-state network maps or metrics to task-related activity [Calhoun et al., 2008; Smith et al., 2009]. Similarities in the topography of RSfMRI networks with task-activation networks [Calhoun et al., 2008; Smith et al., 2009], anatomical covariance networks [Bullmore and Sporns, 2009], white matter fiber-tracked networks [Sui et al., 2014], and electrophysiological networks [Brookes et al., 2011] justify the use of their spatiotemporal dynamics as surrogate markers of the brain’s response to drugs. Because they are task-free, RSfMRI methods are practical in large cohort studies. Commonly, typical RSfMRI studies are conducted at spatiotemporal resolution of TR = 2–3 s, TE = 30–35 ms, 100–200 T2* frames, and 2 mm isotropic resolution explore this dataset and to spatial and temporal because such RSfMRI dataset offers a rich spatiotemporal representation of brain states, it lends itself to various modeling and signal processing approaches. Although the origin of the signal measured in a typical fMRI study remains the same, different analytical
approaches can yield myriad biometrics that are more sensitive to one aspect of neurophysiology than other (Fig. 3). An ongoing and rewarding challenge in RSfMRI research is to use different mathematical formulations to explore different temporal and spectral characteristics of the same data in relation to neurobiological states. In this section we describe several of these methods that are used in pharma-fMRI studies. We will discuss limitations in validity and interpretations of these methods in “Challenges and Limitations.”

**Seed-based analysis**

Over 30% of pharmacological studies surveyed here have relied on region of interest (ROI) seed-based analysis of resting-state functional connectivity. Seed selection is based on *a priori* information about drug actions on local target receptors, hence this method provides a simple answer to the question of how local drug effects propagate across an associated network of regions that collectively subserve a behavior or a (somato)sensory function. For example, a seed in the thalamus can be used to investigate effects of a drug on the sensorimotor network. The seed-based approach simplifies comparison and within-subject reproducibility but, as will be discussed in “Challenges and Limitations,” anatomical variations and heterogeneity of brain regions can lead to “seed selection bias,” and confounds such as proximity to pulsating vessels, motion, susceptibility and registration artifacts can reduce signal to noise ratio. Cole et al. have illustrated that three non-overlapping seeds, all taken from the posterior part of the default mode network (DMN), produce extensive non-overlapping cortical connectivity maps [Cole et al., 2010]. On the plus side, these anatomical variations in network topography help explore the regional specificity of the response of specific brain regions, for example sub-nuclei of the thalamus [Niesters et al., 2014], or subsections of the hippocampus [Khalili-Mahani et al., 2015], to drugs that are expected to target these regions.

Seed-based connectivity analysis is best suited to hypothesis-driven research. In testing the neural circuitry of the dopamine system under the influence of dopaminergic drugs, significant results have been observed focusing on the functional connectivity of seeds from the ventral striatum or the nucleus accumbens [Flodin et al., 2012; Kelly et al., 2009; Konova et al., 2013]. Amygdala and the hippocampus have been used as seeds in studying effects of steroids on the brain [Henckens et al., 2012; Sripada et al., 2014]. Because of the consistent presence of the DMN across different species, its important role in metabolic and behavioral regulation [Raichle et al., 2001], and its importance in mentation during the resting-state, often seeds in the precuneus or medial prefrontal areas are often used to define the strength of the DMN connectivity as a primary biomarker [Boveroux et al., 2010; Flodin et al., 2012; Guldenmund et al., 2013; Scheidegger et al., 2012;
Regional homogeneity (REHO)

REHO is a voxel-based measure of the coherence and synchrony of the BOLD signal fluctuations in adjacent voxels, based on the hypothesis that clusters of neighboring neurons drive intrinsic brain activity. Synchrony is computed using Kendall’s coefficient of concordance (KCC) which measures the ranked correlations at each timepoint among the timeseries of adjacent voxels (usually 27) [Zang et al., 2004]. An alternative to KCC, which measures synchronicity in the time domain, evaluates coherence and synchrony in frequency domain (Cohe-REHO) instead of time domain, and thus eliminates sensitivity to phase variations [Liu et al., 2010]. One advantage of REHO over the seed-based method is that it does not depend on an a priori definition of ROIs and can yield information about the local/regional consistency of activity throughout the brain. A major disadvantage is that the reliability and reproducibility of REHO is highly sensitive to motion and physiological noise, as well as the morphology, thus it requires careful pre-processing and normalization [Zuo et al., 2013]. The functional interpretation of the REHO is still tentative, but there is preliminary evidence that suggests a correlation between neurovascular coupling and REHO variations [Yuan et al., 2013], and that regionally-specific REHO effects under different resting-state conditions, such as eye-closed or eye-open, are associated with differences in global BOLD signal fluctuation in these different conditions [Qing et al., 2015]. Application of REHO in pharma-RSfMRI studies is still limited. REHO has been shown to be sensitive to the normalizing effect of a single dose of methylphenidate on the brains of ADHD children compared with healthy controls [An et al., 2013], however, a placebo-controlled study of a single dose l-dopa and benzodiazepine administration in 81 healthy individuals, showed that seed-based connectivity analysis was statistically more powerful than Cohe-REHO [Flodin et al., 2012]. Given that REHO is an entirely model-free technique for data-mining, further investigation of its viability as a biomarker for dissociating regional and global drug effects under different states is warranted.

Spectral analysis techniques

The spectral characteristics of spontaneous brain activity have long been studied in RSfMRI experiments [Kiviniemi et al., 2000, 2003; Suckling et al., 2008]. Two recent formulations, the amplitude of low frequency fluctuations (ALFF) and fractional ALFF (fALFF), use a Fourier decomposition of the RSfMRI BOLD signal, followed by integration of the amplitudes in a given spectral range, typically in 0.01-0.1 Hz band, to assess the strength of low frequency fluctuations in each voxel (ALFF). Normalization of ALFF by the power in the entire frequency range of the signal (fALFF) represents the relative contribution of a specific frequency band to the whole frequency range [Zou et al., 2008]. Seed- or REHO analyses assess coherence and correlation in temporal characteristics of signal fluctuations. In contrast, regional variations of (f)ALFF provide information about the spectral content of the spontaneous fluctuations in a given voxel independent of its neighboring, regional or network dependencies. Spectral analyses are usually complementary to other RSfMRI metrics such as regional homogeneity and functional connectivity. In a cross-sectional randomized study, comparing effects of l-dopa and benzodiazepine versus placebo [Flodin et al., 2012], fALFF detected moderate local differences between drug groups in the cerebellum which were not detectible with REHO—although fALFF was not as sensitive to detecting cortical effects compared to seed-based functional connectivity [Flodin et al., 2012]. In another randomized placebo-controlled study of intranasal insulin [Kullmann et al., 2013], fALFF revealed a significant reduction of hypothalamic and orbitofrontal power amplitude and a BMI-correlated drug induced change in brain areas involved in cognitive appetitive control. ROI-examination of fALFF in drug-naive Parkinson’s patients versus healthy controls [Esposito et al., 2013a] provided compelling evidence for a band-specific modulation of the sensorimotor network with levodopa. As preprocessing schemes to improve the reliability of fALFF measurements in the presence of spurious noise become more established [Yan et al., 2013a], a re-analysis of many connectivity-based studies might shed a light on the sensitivity of this method to detecting drug-specific neuromodulation.

Independent component analysis and dual regression

The limitations of seed-based analysis are to some extent addressed by the data-driven approach of independent component analysis (ICA). The majority of work reviewed here applies spatial ICA (sICA) [McKeown et al., 1998], which decomposes the 4D spatiotemporal fMRI dataset into a set of “hidden” signals characterized by a spatial map, and associated timecourses of BOLD signal fluctuations. These hidden signals may represent resting-state networks, physiological and subject motion, or other artifacts that all give rise to the measured BOLD signals. In sICA, the decomposition is done in such a way as to maximize statistical independence in the spatial patterns, with no constraints on the timecourses. An alternative approach to sICA is temporal ICA (tICA), which decomposes the 4D spatiotemporal fMRI dataset into spatial maps and timecourses in such a way to maximize statistical independence in the temporal
domain, with no constraints on the spatial maps [Biswal and Ulmer, 1999]. In other words, whereas sICA reveals different brain regions that define a dominant temporal behavior, tICA identifies different temporal behaviors that are dominant in different brain regions. Convergence or divergence of tICA and sICA results depend on assumptions about, for example, spatial versus temporal independence, and existence of spatially and temporally separable components in the data [Calhoun et al., 2012; Tian et al., 2013]. To date, because data in the spatial dimension has been much more abundant (e.g., BOLD signals are measured for many more voxels than timepoints), sICA has dominated the literature. However, fMRI data collected using recent fast acquisition techniques with TRs less than 0.25 s [Feinberg et al., 2010; Posse et al., 2013] have demonstrated the potential of tICA in doing more refined parcellation of brain networks [Smith et al., 2012], and clinical exploration of non-stationarity in spontaneous fluctuations [Miller et al., 2014]. However, these new acquisition techniques are not yet widely available and to our knowledge, they have not been explored in pharmacological studies.

Application of ICA to pharma-RSfMRI data was first done by [Kiviniemi et al., 2003], who used FastICA to analyze fMRI data collected in 15 anesthetized children. They were able to successfully delineate large vascular regions, as well as primary and sensory cortical areas in separate component maps. The discovery of consistent and functionally relevant ICA networks [Beckmann et al., 2005; Damoiseaux et al., 2006] has made this technique a common choice for identifying the functional topography of networks in an individual or in a group of subjects. It is common to perform a group ICA (gICA) by concatenating the data across subjects, in order to obtain a single representation of the spatiotemporally independent functional topographies. The gICA maps are then used as a template in a two-step multivariate regression analysis to identify subject-specific spatial maps and timecourses that capture any group or condition differences (e.g., network changes between placebo and drug). This process is called dual regression (DR): the first regression defines the timecourse of fluctuations in each network; and the second regression examines the relation between these network-specific fluctuations and the fluctuations within each voxel of the brain. In gICA/DR studies, the choice of networks of interest (NOIs) is usually limited to 8–20 networks that resemble the most common network anatomies. In theory, by increasing the number of independent components, one might explore finer-grained network topographies. However, component ordering and selection in ICA is very challenging, as this methods is also sensitive to detecting structured noise, and physiological and motion artifacts that diminish the reliability of component detection [Zuo et al., 2010a]. Techniques such as ICASSO [Himberg and Hyvarinen, 2003] and RELICA [Artoni et al., 2014] have been proposed to help identify the most reliable independent components, or to reject the most likely spurious ones [Salimi-Khorshidi et al., 2014]. Yet, to fully automate the selection of functionally relevant components is not easy. A proposed workaround is to use predefined NOIs (instead of seeds) as template networks, and then proceed with DR. Group/condition differences in network connectivity are then assessed by higher-level statistical analysis on these subject-specific spatial maps.

GICA/DR and NOI/DR approaches are very common, and they are vastly used in pharma-RSfMRI studies [Boveroux et al., 2010; Cole et al., 2013; Esposito et al., 2013b; Greicius et al., 2008; Guldenmund et al., 2013; Jordan et al., 2013; Khalili-Mahani et al., 2012; Klaassens et al., 2015; Klumpers et al., 2012; Licata et al., 2013; Mueller et al., 2014; Niesters et al., 2012, 2014; Roseman et al., 2014; Tanabe et al., 2011]. Similar to seed-based analysis, NOI/DR-based analyses are easy to standardize and accommodates replication studies, however issues related to nonstationarity of functional networks needs to be further explored (see “Challenges and Limitations”).

Graph theoretical approaches

Almost 15% of studies surveyed here have explored drug-induced effects on network properties. Graph-based metrics are derived from mathematical equations that examine the global relations between regions whose connectivity is determined from seed/NOI or ICA based analysis. Whereas seed- and ICA-based approaches reveal network topographies by finding areas that fluctuate in a similar and correlated manner, graph theoretical methods reflect the net value of global interaction in the brain. Metrics such as local and global network efficiency, network modularity and integration, path length, clustering coefficients, and small-worldness serve as surrogate markers of the efficiency with which neural information propagates across brain regions. Compared with other metrics (connectivity, coherence or spectral power), which reflect the functional anatomy of the drug effect, graph metrics are more suitable for studying whole-brain dynamics. This interpretation is supported by the observation of network-wide variations linked to cerebral blood flow [Liang et al., 2013] and glucose metabolism [Tomasi et al., 2013].

As will be discussed in “Pharmacological Probing of Neural Networks,” pharmacological studies involving anesthetics have been critical in validation of these graph metrics, by finding association between their features and states of conscious mental activity. For example, reduced local and global efficiency of cortical regions are detected during light chloral hydrate sedation in children [Wei et al., 2013] and during loss of consciousness in propofol sedation in adults [Monti et al., 2013], indicating that global network efficiency can serve as a biomarker of the state of consciousness. Although these global effects may reflect the global state of consciousness and metabolism, the regional network properties do not change in a single direction. For example, it has been shown that nicotine causes significant variations in local efficiency of the brain
networks, with significant increases in the regional efficiency of thalamus and putamen and large decreases in the regional efficiency of basal ganglia, while leaving the primary sensory and motor regions unchanged [Wylie et al., 2012]. Another graph-metric is eigenvector centrality (EC) that indicates how each brain region connects to the most important brain hubs [Lohmann et al., 2010]. A significant increase in hypothalamic EC has been detected in response to viewing food pictures under Exenatide (vs. placebo condition) a drug that is expected to alter energy uptake by blocking the glucagon-like peptide-1 receptors in the hypothalamus [Schlogl et al., 2013]. Significant decreases in EC in the thalamus and the brainstem have been observed in response to mild propofol sedation [Gili et al., 2013]. Using the method developed by [Lohmann et al., 2010], anatomically distinct and drug-specific effects of morphine (decreases in EC in cerebellum, caudate and putamen, and increases in anterior cingulate and retrosplenium) and alcohol (decreases in EC in cerebellum, hippocampus and subthalamic nuclei and an increase in anterior cingulate cortex) have been discovered in regions other than those detected from dual regression and parametric CBF mapping (see Fig. 6).

Different graph metrics can be explored to describe different properties of brain networks. For instance, Schroter et al. [2012] have demonstrated that, compared with wakeful state, propofol-induced loss of consciousness is associated with a decrease in general connectivity strength particularly in the hub regions (thalamus, putamen and associative areas) and decrease in whole brain integration. In contrast, propofol treatment has been associated with increases in clustering ratio and small worldness. These effects have been interpreted as a decoupling of cortical processing from information integration in the brain [Schroter et al., 2012]. While corroborating these findings in another similar study, Monti et al. [2013] have noted that clustering ratio and small worldness are not specific to states of consciousness, and remain elevated through post-sedation recovery, suggesting that the change in these metrics are not solely related to the drug action in the brain, but perhaps also related to the state of brain in response to loss of consciousness [Monti et al., 2013].

These variables are explored in conscious states as well. It has been shown that catecholaminergic depletion of dopamine is associated with reduced global and local efficiency of brain networks, within a range that is compatible with a small-world topology, and reduced regional efficiency of amygdala and orbitofrontal networks [Carbonell et al., 2014b]. These network-wide changes associated with dopamine down-regulation have been interpreted as underlying cognitive impairments that accompany dopaminergic dysfunction in Parkinson’s disease or schizophrenia. In the same vein, Wylie et al. [2012] have studies the effect of cholinergic modulation with nicotine, and have reported a significant increase in local efficiency and significant increases in regional efficiency of the limbic and paralimbic areas, suggesting that nicotine influences cognition by increasing the efficiency of communication within the brain [Wylie et al., 2012]. These examples, underline the potential of pharmacological studies in illuminating the large-scale network properties of the brain and how they relate to higher behavioral or cognitive states. However, as it will be discussed in “Challenges and Limitations” reproducibility and reliability of graph metrics is contingent on strict preprocessing and analytical assumptions.

Hierarchical clustering

Techniques such as s/tICA parcellate the brain into spatio/temporally independent networks, and graph theoretical metrics reflect the states of integration of neuronal activity in brain networks. Hierarchical clustering techniques combine the two by generating information about the scale space of functional specialization and functional integration [Marrelec et al., 2008], yielding a more fine-grained representation of how different brain sub-networks interact and organize under normal or abnormal (e.g., drug-influenced) conditions. (For a comprehensive review, see [Craddock et al., 2015].) Hierarchical clustering is a model-free approach that parcellates the brain into biologically and anatomically meaningful spatial scales [Bellec et al., 2010; Kelly et al., 2012; Power et al., 2011; Smith et al., 2013]. Hierarchical clustering can be used to study functional modularity, that is, the extent to which the brain is divided into communities with connections of different strength. Clinical viability of studying network hierarchy has been established in demonstrating reduced hierarchical organization in functional brain connectivity of schizophrenic patients versus healthy controls [Bassett et al., 2008], in Alzheimer’s patients versus healthy controls [Xia et al., 2014], in epileptic patients [Dansereau et al., 2014] and even in relation to impulsivity [Davis et al., 2013]. These techniques have not been extensively reported in pharmacological neuroimaging, however promising examples exist. Schrouff et al. showed that sedation with propofol reduced integration of information within and between six well-known ICA-identified networks, excluding the ventral attention network, thus suggesting functional specificity of the method [Schrouff et al., 2011]. Hierarchical clustering has been used to illustrate a reduction in modularity of resting-state brain networks under acute dopamine depletion, consistent with the expected role of dopamine in functional integration [Carbonell et al., 2014b].

Network hierarchies can also be explored to study the dynamics of brain function and non-stationarity. Methods such as BASC [Bellec et al., 2010] perform multi-level bootstrap analysis to identify stable cluster hierarchies, and aberrations in epileptic patients versus healthy controls [Dansereau et al., 2014]. Network hierarchies can be plotted as multi-resolution curves over a range of temporal, spatial, geometric and structural scales [Lohse et al., 2014].
To study the dynamics of reconfigurations of network hierarchies in relation to mental states [Bassett et al., 2011; Cole et al., 2014; Jones et al., 2012] will be a potentially important method in PK/PD modeling (discussed in “Experimental Objectives and Clinical Relevance” and “Challenges and Limitations”).

**Arterial Spin Labeling and Cerebral Perfusion**

Cerebral perfusion is an important pharmacodynamic endpoint. It depends on a number of factors including the viscosity of blood, vascular anatomy and pathology, systemic factors like cardiac output, end-tidal CO₂, neuronal activity and the encompassing cerebrovascular autoregulation [Ainslie and Duffin, 2009]. Autoregulation refers to the ability to maintain constant cerebral perfusion over a wide range of perfusion pressures. Cerebrovascular resistance is, however, influenced by many more (physiological) parameters, including arterial carbon dioxide levels, cerebral metabolic rate of oxygen or glucose consumption, neural activation, activity of the sympathetic nervous system, posture and other physiological variables. Under normal resting conditions, it is expected that global cerebral blood flow would be relatively stable but under pharmacological stimulation, variations in CBF become an important index of how the drug interacts with cerebrovascular autoregulation.

Cerebral perfusion can be measured with arterial spin labeling (ASL) techniques, which use radiofrequency pulses to magnetically label the water molecules in the arterial blood at the base of the brain for several seconds (1.5–2.0 s), followed by a readout of the signal within the brain after a few seconds of delay to allow blood to flow to the upstream tissue. Subtracting this labeled image from a second image acquired without labeling the inflowing blood, results in a perfusion-weighted image that can be used to calculate cerebral blood flow in units of mL/100 mL tissue/min, using a biophysical model based on parameters of acquisition, physiological constants and validated models of “normal” cerebral hemodynamics [Alsop et al., 2014; Buxton et al., 1998; Buxton, 2005].

Quantitative methods such as ASL are reliable if acquisition protocols are well standardized [Alsop et al., 2014]. Consistency of CBF estimation with background-suppressed pCASL has been established in multi-center and multi-acquisition reproducibility studies [Gevers et al., 2011; Vidorreta et al., 2013]. Intersession, intrainserter and inter-scanner reproducibility across different vendors suggests that normalizing acquisition parameters on different machines yields stable measurements of the gray matter perfusion. However, in presence of differences in acquisitions sequences, spatial differences caused by different smoothing behavior of the readout module become problematic [Mutsaerts et al., 2014; Mutsaerts, 2015; Vidorreta et al., 2013].

Various ASL acquisition schemes exist which differ in implementation and compatibility with scanner hardware. The most commonly available sequences are pulsed, (pseudo)-continuous and velocity-selective ASL (PASL, pCASL and VS-ASL, respectively) [Wong, 2014]. See Figure 4 for a schematics representation of labeling differences in each method. Currently, pCASL in combination with background suppression and a (segmented) 3D readout has been proposed as the work-horse technique for clinical experiments [Alsop et al., 2014]. Many of the arguments that led to the advice to use pCASL in radiological applications, such as signal-to-noise ratio (SNR), robustness, and availability [Deibler et al., 2008a,b], also hold true for applications in pharmacological imaging experiments. More complex methods such as time-encoded ASL [Teeuwisse et al., 2014], and velocity- and acceleration selective ASL [Schmid et al., 2014; Wong et al., 2006], are likely to become valuable assets in PK/PD modeling, but no feasibility studies have been presented so far. Here, we focus on three of the most common applications of resting state-ASL measures used in pharmacological studies.

**Global cerebral blood flow**

Global CBF is computed by averaging the quantitative CBF values over the entire brain, or more commonly, over the gray matter (GM) regions, which have much higher baseline CBF than white matter (WM) (~60 mL/100g/min versus ~20 mL/100g/min). The global CBF is a single value estimated over a specific period of time, that constitutes a pharmacodynamic endpoint in dose-response experiments [Fernandez-Seara et al., 2011; Marxen et al., 2014; Strang et al., 2015].

The reliability and reproducibility of global CBF over a 1-year period (4 time points) has been demonstrated in cognitively normal subjects [Jiang et al., 2010]. Recently, in an O¹⁵-H₂O PET/pCASL validation study involving hypercapnia in the same population, precision, accuracy and high correspondence of pCASL-based quantification of global CBF with O¹⁵-H₂O PET (the current gold standard) has been established [Heijtel et al., 2014]. It has been shown that within-subject, between-time or between-session values measured on the same scanner are stable in the absence of drugs, but change significantly with drug administration [Khalili-Mahani et al., 2011], and return to baseline levels, for example, after ketamine washout [Khalili-Mahani et al., 2015]. Although global CBF is a reliable marker for within-subject comparisons, it should not be treated as a quantitative measure for between-subject comparisons. Between-subject baseline values are expected to vary within a normal range predicted from the physical modeling of the ASL signal, however differences in acquisition parameters, modeling, and stereotaxic positioning of tag pulses with respect to arteries can influence the absolute quantitative values. Therefore, it is important to be vigilant about validation protocols that establish limits of the model in presence of acquisition noise or between-
subject variations in physiology or anatomy. For this reason, it is common to examine relative CBF, normalized to a within-subject global CBF.

**CBF mapping**

Voxel-based perfusion maps yield a snapshot of changes of the spatial distribution of CBF, and are well suited for drug fingerprinting. A handful of pharma-fMRI studies to date have employed ASL for examining regional changes relative to placebo, in response to metoclopramide [Fernandez-Seara et al., 2011], alcohol [Khalili-Mahani et al., 2011; Marxen et al., 2014; Strang et al., 2015; Tolentino et al., 2011] morphine [Khalili-Mahani et al., 2011], ketamine [Khalili-Mahani et al., 2015], psilocybin [Carhart-Harris et al., 2012], MDMA [Carhart-Harris et al., 2015], THC [Van Hell et al., 2011], remifentanil [MacIntosh et al., 2008] and caffeine [Mutsaerts, 2015]. Because most CNS drugs show both a global and a local CBF response, it is interesting to study inter-regional differences in CBF maps by isolating the global CBF effects. There are several approaches to achieve this. The simplest method is to normalize CBF voxel-wise by taking the ratio of blood flow at each voxel to global CBF or to CBF in a control region of interest [Fernandez-Seara et al., 2011]. More complex approaches to computing relative CBF involve modeling the effects of a drug on cerebral perfusion with respect to variations in label-control CBF pairs over time and in

---

**Figure 4.**

Schematic representation of ASL tagging and acquisition frames. Top row: Pulsed ASL (PASL) which provides high labeling efficiency, but low SNR; pseudo-Continuous ASL (pCASL) has higher SNR, but is susceptible to magnetic field disturbances, arterial velocities, arterial anatomy and tag position; velocity-selective ASL (VS-ASL) does not require spatial selectivity as it tags all inflowing spins as long as they are above a certain velocity threshold. By including a second velocity selective module just before signal readout, signal from venous blood is suppressed, since that normally accelerates upon return. Middle row, an example of quantified CBF measured using background-suppressed pCASL. Lower Row, Regional differences in arterial transit time.
relation to expected pharmacodynamics [Marxen et al., 2014], for example, using a general linear models (GLM) approach.

Although many of pharmacological ASL studies report regional CBF variations in brain areas with higher affinity for drug’s target receptors, this does not necessarily mean an increased activation in the co-localized excitatory systems [Wagner et al., 2007]. Numerous cofactors such as interneurons, inhibitory receptors, as well as adaptive functional changes due to higher-level processing of the interoceptive or proprioceptive states (e.g., placebo) [Wager et al., 2007] may impact regional effects. For example, factors such as fatigue [Lim et al., 2010] and respiration rates [Khalili-Mahani et al., 2011] can influence both regional and global CBF values. Thus, relation between CBF and drug effects must be interpreted carefully.

Arterial transit time

ASL can also be used to map other physiological parameters, such as the arterial transit time (ATT, or arterial time of arrival), which is the time it takes labeled blood to travel from the labeling plane to the imaging regions. Changes in ATT can be thought of both as a hemodynamic parameter that can help localize cerebrovascular effects of a drug, and as a nuisance parameter that introduces errors in the CBF quantification model. MacIntosh et al. [2008] found a spatially variable pre-drug arterial transit time, ranging from 340 ms in the superior frontal region, to 600 ms in the putamen and insula. Brain regions with the largest ATT had the largest change in response to drug (slowing down by 10–11 ms after drug infusion). ATT measurements are easily obtained in PASL, but not with the standard pCASL acquisition protocols [MacIntosh et al., 2008]. Combined perfusion and ATT measurements are possible with multi-timepoint ASL as well as time-encoded pCASL [Teeuwisse et al., 2014]. These advanced techniques come, however, at a price, as they can suffer from lower SNR, lower temporal resolution, increased technological complexity, poorer robustness or a combination of these.

Combined ASL/BOLD fMRI and Neurovascular Coupling

The BOLD signal is a combination of variations in blood oxygenation, metabolic rate of oxygen consumption, cerebral blood volume and cerebral blood flow. The complexity of neurovascular coupling in RSfMRI studies has been previously reviewed [Liu, 2013], and using a combined ASL/BOLD fMRI acquisition, together with metabolic calibration methods have been proposed to disambiguate the neuronal and vascular components of drug effects. Only a handful of pharma-fMRI experiments have acquired both ASL and BOLD-fMRI in the same experiment, and in most cases not simultaneously [Carhart-Harris et al., 2015; Denier et al., 2012; Griffeth et al., 2011; Khalili-Mahani et al., 2014, 2015; Nasrallah et al., 2012; Perthen et al., 2008; Qiu et al., 2008; Rack-Gomer et al., 2009; Van Hell et al., 2011].

In the simplest form, ASL and BOLD-RSfMRI acquisitions are made consecutively and analyzed jointly. For example, Carhart-Harris et al. [2015] showed in humans that changes in CBF after administration of 3,4-methylenedioxymethamphetamine (MDMA) were also accompanied by changes in BOLD resting-state functional connectivity in brain regions such as the amygdala and hippocampus and that the functional changes in CBF and BOLD functional connectivity were related to the global subjective effects of MDMA. Conversely, using a conjunction analysis approach, Khalili-Mahani et al. [2014] showed that BOLD-related connectivity and CBF correlations under a morphine condition were most consistent in the prefrontal networks and most uncorrelated in the sensorimotor area.

More elaborate acquisition techniques such as dual echo PCASL [Dai et al., 2008] allow to acquire BOLD/CBF measurements simultaneously in order to investigate the neurovascular coupling with higher temporal precision [Fukunaga et al., 2008; Gauthier and Hoge, 2012; Tak et al., 2015; Wu et al., 2009]. In one such pharmacological experiment, Qiu et al. [2008] estimated both BOLD and relative CBF after sevoflurane anesthesia induction or after withdrawal of sevoflurane in healthy subjects, and showed that CBF and BOLD remained coupled under anesthesia although the coupling rates varied spatially.

To disentangle the neurovascular component of brain activity from the measured BOLD signals, the simultaneous BOLD/CBF data collected during rest are “calibrated” (via a biophysical model) using a separate scan with the same acquisition parameters and under controlled administration of gases (CO2 or O2) or breath-holding. This, a form of phfMRI itself, is the gold standard for evaluating the rate of change in neuronal activity, perfusion and cerebral metabolic rate of oxygen consumption (CMRO2). For review, see [Hoge, 2012]. Pharmacological interventions further complicate the “calibration” of the hemodynamic response. For example, in studies of caffeine, it has been shown that factors such as dosage and history of exposure determine activation of different receptor subtypes [Chen and Parrish, 2009b, 2009a], which cause opposite vascular responses depending on dose or exposure history [Diukova et al., 2012; Griffeth et al., 2011]. The need for gas challenges (CO2 for hypercapnia, or O2 for hyperoxia) or breath holding [Bright and Murphy, 2013a; Lipp et al., 2015; Madjar et al., 2012] for calibration makes this technique impractical for most pharmacological studies. However a promising new technique by Blockley et al. [2012, 2015] utilizes MR pulse sequences as a means of estimating the parameters in the BOLD biophysical model, obviating the need for a gas calibration scan. Such quantitative approaches in drug studies will be important for better modeling of neuronal, vascular and metabolic factors that modulate brain activity under different drugs.
EXPERIMENTAL OBJECTIVES AND CLINICAL RELEVANCE

Neuropharmacological research encompasses a broad range of exploratory, proof-of-concept and clinical objectives. Drug classes and expected pharmacodynamics often influence experimental design—also the cost. Generally, pharma-fMRI experiments investigate relationships between drug actions and brain function in terms of (1) neurophysiological changes resulting from drug interactions with specific target receptors; (2) alteration of activity of other neuropeptides in downstream pathways and (3) peripheral and nonspecific physiological responses in organs other than the brain. Figure 5 illustrates the proportion of different drug classes studied to date in relation to common study objectives in the literature surveyed here.

Drug Fingerprinting

Drug fingerprinting (FP) refers to characterizing the drug-specific topography of brain activation, assuming that drugs modulate the neuronal activity in brain regions that have a preferred neurotransmitter affinity (i.e., higher receptor density, higher affinity or higher binding potential) for that drug. However, drugs rarely act on just one neurotransmitter, and often produce overlapping side effects (e.g., most antipsychotic drugs are also sedative, or drugs used to treat Parkinson’s Disease may lead to psychosis or anxiety side effects). For this reason, it is important to define fingerprinting realistically: FP does not refer to the ability to identify a unique signature of a particular drug effect in the brain, rather it refers to methods that help tease apart the drug-specific actions from common effects. To identify whether a drug acts on a specific neural pathway is important for target identification and clinical design. As such, FP requires a model-free and generalizable analytical technique that helps characterize the full profile of brain's drug-distinct and physiologically-common responses to different drugs across populations.

To localize the effect of drugs in the brain is the primary objective of more than 30% of studies surveyed here (see Table I and Fig. 5).

In an early FP study (Leiden fingerprinting study, Fig. 1), it was shown that the NOI-based dual regression (DR) method provides a sensitive framework for detecting compound-specific effects in resting-state brain networks [Khalili-Mahani et al., 2012]. A similar analytical approach has been used to explore the effects of psilocybin versus MDMA [Roseman et al., 2014]. The NOI/DR method has been used to study the effects of a single compound on the topography of resting-state networks under PK-controlled administration of THC [Klumpers et al., 2012; Van Hell et al., 2011], ketamine [Niesters et al., 2012] and bupivacaine [Niesters et al., 2014]. ASL has proven to be a sensitive method for FP studies of alcohol [Khalili-Mahani et al., 2011; Marxen et al., 2014; Strang et al., 2015], opioids [Khalili-Mahani et al., 2011; Kofke et al., 2007; MacIntosh et al., 2008] and THC [Van Hell et al., 2011].

Other examples of FP experiments without pharmacokinetic modeling include mapping the effects of nicotine [Tanabe et al., 2011], methylphenidate [Mueller et al., 2014] or amphetamine [Esposito et al., 2013b] and serotonin [Klaassens et al., 2015]. The objective of FP has also been explored in studying the effect of receptor agonist and antagonists in cross sectional designs, for example, comparing functional connectivity in response to levodopa versus haloperidol [Cole et al., 2013], or the NMDA antagonist ketamine versus the glutamate suppressant lamotrigine [Deakin et al., 2008; Doyle et al., 2013].

Dose/Response in Anesthesiology

PhmMRI was first conceived to address the questions related to dose responses in the brain during administration
of different doses of anesthetics and analgesics. In these studies (depicted in Fig. 1B), the magnitude of change in the BOLD signals measured over the timecourse of drug infusion and washout is fit to the pharmacokinetic profile of anesthetics such as morphine [Becerra et al., 2006; Leppä et al., 2006], buprenorphine [Upadhyay et al., 2011] and ketamine [De Simoni et al., 2013]. Seed- or network-based connectivity analyses of Pharma-RSfMRI data have also proven sensitive to detecting dose response effects in the brain. Dose dependent variations in the motor network (identified by a seed in M1 cortex) under different stages of anesthesia with different doses of sevoflurane were first demonstrated by [Peltier et al., 2005]. Using the putamen as a seed, Upadhyay et al. showed a dose-dependent decreases in functional connectivity of the somatosensory and sensorimotor networks [Upadhyay et al., 2012] under buprenorphine, with a topography that closely resembled an NOI-based analysis of the morphine effect on these networks in an independent study [Khalili-Mahani et al., 2012].

Prominent effects in the hippocampus and sensorimotor networks. A dose-dependent increase in functional connectivity of the frontoparietal and thalamocortical regions has been shown to correlate with pain perception in spinal anesthesia using bupivacaine [Niesters et al., 2014]. A dose-dependent ketamine-induced increase in the functional connectivity of the corticohippocampal subnetworks has also been reported concurrent with reduced alertness states [Khalili-Mahani et al., 2015].

Anesthetics have often been used to gain a better understanding of the clinical relevance of resting-state fMRI biomarkers (see “Methods Validation and Calibration” for details). Derivative biomarkers such as network properties, coherence or spectral power, have been used to study the global effects of drugs on the brain, in terms of the reconfiguration of resting-state networks under sedation with propofol [Gili et al., 2013; Jordan et al., 2013; Monti et al., 2013; Schrotter et al., 2012; Schrouff et al., 2011], chloral hydrate [Wei et al., 2013] and sevoflurane [Peltier et al., 2005; Qiu et al., 2008].
As will be discussed in “Challenges and Limitations,” dose/response evaluation, also known as pharmacokinetic/pharmacodynamic (PK/PD) modeling is one of the most challenging, but also most important goals of pharmacological neuroimaging.

**Pharmacological Probing of Neural Networks**

In pharmacological probing, the effects of a given dose of a neuroreceptor agonist/antagonist or blocker are investigated in order to test an *a priori* hypothesis about the relationship between the drugs mechanism of action on a region or a system, and the neuropsychological function targeted by that drug. Pharmacological probing experiments can serve several research objectives.

**Systems neuroscience**

In the simplest designs, pharmacological probing can be used to investigate the neuro-circuitry of a given neurotransmitter-signaling pathway in animals or humans. (See Fig. 5 for a summary of the most commonly tested neurotransmitter systems.)

Pharmacological probing of the dopaminergic system with direct or indirect targeting of the dopamine receptors has been well-studied [Carbonell et al., 2014b; Cole et al., 2013; Fernandez-Seara et al., 2011; Flodin et al., 2012; Kelly et al., 2009; Mueller et al., 2014; Ramaekers et al., 2013; Vytlacil et al., 2014]. For instance, Cole et al. compared the effects of the dopamine agonist levodopa and the dopamine antagonist haloperidol against placebo on large-scale network connectivity using group ICA and dual regression, and found a dichotomous pattern of activity in the connectivity of the anteromedial cortical areas to the DMN: compared with levodopa, haloperidol administration was associated with higher positive correlations between the DMN and left pre-central and middle frontal gyri, and higher negative correlations between the DMN and the supramarginal gyrus and intraparietal sulcus. Haloperidol induced modulation of the connectivity in these regions was also associated with behavioral scores, with higher negative connectivity predicting higher impulsivity [Cole et al., 2013].

With a growing understanding of the role of glutamatergic dysregulation in various neurological and psychiatric disorders [Krystal et al., 2003], pharmacological probing of the NMDA receptor system is becoming a more active area of research as well [Becerra et al., 2009; De Simoni et al., 2013; Deakin et al., 2008; Doyle et al., 2013; Driesen et al., 2013; Gass et al., 2014; Grimm et al., 2015; Khalili-Mahani et al., 2015; Li et al., 2014; Niesters et al., 2012; Scheiddegger et al., 2012]. In the first study of its kind, Deakin et al. [2008] probed the glutamatergic system using an NMDA-receptor antagonist to test an experimental model of schizophrenia and demonstrated a significant ketamine-induced reduction of the BOLD signal in the antero- and posteromedial regions, that was significantly associated with psychosis scales [Deakin et al., 2008]. Taking a different analytical approach, Driesen et al. [2013] showed a significant correlation between increase in global connectivity and increased psychotic-like and social withdrawal and cognitive distraction scores [Driesen et al., 2013]. In an elaborate partial-crossover design, Doyle et al. [2013] used two different pre-treatments with lamotrigine (300 mg, oral single dose, an anticonvulsant drug that directly inhibits glutamate release) and risperidone (2 mg, oral single dose, an antipsychotic drug that acts on the serotonergic system and indirectly inhibits glutamate release) to provide evidence that ketamine modulation of the resting-state BOLD amplitude is linked to glutamate release [Doyle et al., 2013]. Importantly, by showing distinct regional interactions of risperidone and lamotrigine with ketamine (compared with placebo), this study offered further evidence for the plausibility of such experimental designs in drug fingerprinting.

From a different perspective, Khalili-Mahani et al. [2015] used ketamine to test the “hippocampal negative feedback inhibition of the HPA axis” model [Khalili-Mahani et al., 2010; Pruessner et al., 2008], and asked whether a pharmacological blockade of NMDA-receptors would cause a deactivation of the hippocampus and trigger a neuroendocrine stress response due to disinhibition of the hippocampal controlled HPA axis. In fact a reduction of hippocampal CBF relative to the rest of the brain, concomitant with increased cortisol secretion, and increased cortico-hippocampal connectivity that correlated with changes in states of alertness was observed [Khalili-Mahani et al., 2015]. An independent research group has reported a similar increase in cortico-hippocampal connectivity in both men and mice [Grimm et al., 2015].

The GABAergic system is often associated with inhibitory neuronal activity, and pharmacological stimulation with drugs such as zolpidem and alcohol that act on GABA receptors. For example, it has been shown that alcohol and zolpidem decrease activation of visual cortex during visual stimulation [Calhoun et al., 2004; Levin et al., 1998; Licata et al., 2011]. However GABAergic drugs have been shown to increase functional connectivity within many cortical regions [Licata et al., 2013, Esposito et al., 2010; Greicius et al., 2008; Khalili-Mahani et al., 2012; Kiviniemi et al., 2005]. Specifically, zolpidem increased resting-state functional connectivity within auditory, visual, motor, and limbic networks [Licata et al., 2013]; midazolam enhanced BOLD signal synchrony within visual, auditory, and motor cortices during conscious sedation [Greicius et al., 2008; Kiviniemi et al., 2005], and alcohol also increased the connectivity strength in the auditory, somatosensory, sensorimotor, cerebellar, and visual RSNs [Esposito et al., 2010; Khalili-Mahani et al., 2011]. Although interpretation of these studies is still tentative, they illustrate that RSfMRI connectivity analysis provides a complementary view of brain’s activation states, which challenges the assumptions of deactivation at the receptor site, and suggests wide spread effects of GABAergic signaling on the entire brain.
Disease mechanisms

To differentiate disease-related aberrations in neural function, by using drugs that target brain regions or neurotransmitters affected by the disease, is another objective of probing studies. Pharmacological stimulation of the dopaminergic system has been tested in search of biomarkers that differentiate the states of brain activity in AD/HD [An et al., 2013], in Parkinson’s disease versus normal [Esposito et al., 2013a], and in addiction to heroine [Denier et al., 2013; Schmidt et al., 2015] and cocaine [Konova et al., 2013, 2015; Kufahl et al., 2005]. With growing interest in the glutamatergic underpinnings of mood and anxiety disorders, several RSfMRI studies have attempted to probe variations in resting-state functional connectivity during pharmacological perturbation of the NMDA receptor system [De Simoni et al., 2013; Doyle et al., 2013; Khalili-Mahani et al., 2015; Scheidegger et al., 2012]. Yet in other studies, differences in cognitive control between healthy adult and alcohol-dependent individuals have been probed using stimulants such as modafinil [Schmaal et al., 2014] and differences in emotional systems in patients with anxiety disorder and healthy controls have been probed with oxytocin [Dodhia et al., 2014]. Even sucrose has been used to investigate differences in the neural correlates of metabolic regulation between healthy obese and lean individuals [Kilpatrick et al., 2014].

Methods Validation and Calibration

Resting-State fMRI has exponentially grown in popularity; however, the majority of studies to date are correlational or methodological investigations. Pharmacological experiments offer an important opportunity to study causal relationships, and increase the biological impact of RSfMRI findings. Greicius et al. [2003] validated their theory about the role of the DMN in sustaining the states of consciousness [Greicius et al., 2003] by comparing functional connectivity during administration of midazolam in a sedated but awake state versus a resting unsedated state [Greicius et al., 2008]. The link between the DMN and states of consciousness has also been studied under propofol [Boveroux et al., 2010; Stamatakis et al., 2010]. The general resting-state brain activity related to consciousness states has also been investigated in other relay hubs such as the thalamus and brainstem [Guldenmund et al., 2013].

Similarly, drugs can be used to “calibrate” neuroimaging variables, such as the BOLD signal and blood flow. For example, based upon a priori hypotheses about the vasoconstrictive properties of caffeine [Rack-Gomer et al., 2009; Tal et al., 2013; Wong et al., 2012; Wu et al., 2014], and the vasodilatory effects of CO2 [Gauthier et al., 2012; Wise et al., 2004b; Xu et al., 2011], these substances have served as “non-invasive” neurochemical modulators of the neurovascular components of the BOLD signal to study neurovascular coupling.

Finally, pharmacological calibration may lead to more accurate models of the BOLD/CBF relationship. Although the correlation between BOLD fluctuations and cerebral blood flow in brain networks is significant [Chuang et al., 2008], this relationship is not uniform across the brain [Khalili-Mahani et al., 2014; Li et al., 2012]. Using drugs to manipulate brain physiology may help clarify to what extent this heterogeneity arises from spatial variations in cerebrovascular physiology [Liu, 2013] or from regional chemorarchitecture affecting neuromodulation [Zilles and Amunts, 2009]. This insight will be critical for developing more accurate models to describe the relationships between brain metabolism, neuronal activity and vascular reactivity.

Animal Research

Drug development and basic neuroscience discovery hinge on animal-to-human translation. Methodological issues related to animal phMRI studies have been long investigated [Gozzi et al., 2005, 2007; Schwarz et al., 2003, 2006]. In vivo mapping of the functional connectivity of neurotransmitter networks of the animal brain under drugs was first introduced by Schwarz et al., who have since explored and validated various approaches to animal phMRI analysis [Schwarz et al., 2007a,b, 2007c, d]. With methods being established and availability of ultra-high field (>9 Tesla) scanners, rodent pharma-RSfMRI is likely to become a very active research field. A full review of challenges of animal fMRI is beyond the scope of the current review. For a recent review of the promising implications of this method, see Jonckers et al. [2013]. However, some animal studies have been specifically conducted to validate several of the RSfMRI biomarkers used in humans. To date, animal pharma-RSfMRI studies have:

- established a link between spontaneous electrophysiological and hemodynamic fluctuations measured in rat brain by measuring EEG and BOLD signal [Liu et al., 2011; Nasrallah et al., 2014a; Otte et al., 2014], and by pharmacological manipulation of the mitochondrial Ca++ influx [Sanganahalli et al., 2013];
- detected reproducible set of anatomically distinct resting-state network from ICA of BOLD signal fluctuations in rats [Becerra et al., 2011] and mice [Mechling et al., 2014] and characterized similarities and differences between rats and mice [Jonckers et al., 2011], thus providing a methodological framework for standardized model-free exploration of drug effects on the brain of different species;
- illustrated different patterns of resting-state connectivity with different anesthetics (isoflurane, alphachloralose and medetomidine) [Williams et al., 2010], or adrenergic agonists versus antagonists [Nasrallah et al., 2014b], thus providing evidence for the sensitivity of the methods to detecting receptor-specific
effects. These findings confirm potential biases that are expected from interactions of the anesthetic drugs with the test compounds [Gozzi et al., 2008].

- illustrated that the functional network topography [Liu et al., 2013b], and spectral power [Magnuson et al., 2014] of the spontaneous fluctuation in the BOLD signal were dynamically altered by different doses of the anesthetics isoflurane and medetomidine [Nasrallah et al., 2014a], even at different stages of coming out of anesthesia during ketamine washout [Bettinardi et al., 2015];

- And last but not least, illustrated the efficacy of the technique in fingerprinting and pharmacological probing by providing evidence of homologous effects of an opioidergic drug, buprenorphine, in humans and in rats [Becerra et al., 2013], by detecting changes in the dopaminergic system after haloperidol [Gass et al., 2013] administration, and by detecting changes in the glutamatergic system (including hippocampus and medial prefrontal cortex) with the NMDA antagonist memantine [Sekar et al., 2013].

These findings strengthen the case for applicability of RSfMRI in translational neuroscience.

### CHALLENGES AND LIMITATIONS

For pharma-RSfMRI to be clinically viable, three aspects of reliability, reproducibility and sensitivity are critical. First, it must be established that the biomarkers are reliable and robustly reproducible. Next, those biomarkers must be able to measure drug effects with a certain degree of statistical reliability within a standardized framework, and third, the models used to assess effects must be clinically meaningful.

So far, we have shown applications of different fMRI biomarkers and provided evidence from existing studies to illustrate the clinical plausibility of these metrics to characterize regional and global effects of drugs in the brain. However, several limitations in study design and analysis that remain to study further.

#### Biological Confounds

As discussed in “Basics and Biomarkers,” both BOLD and ASL measurements relate to cerebral blood flow, which is tied to autoregulation and is affected not only by the direct modulation of neuronal activity at the site of drug receptors, but also by indirect modulation of the endocrine system, overall metabolic rate and the cardiopulmonary function that may demand an autoregulatory response from the brain (Fig. 1). These interdependences challenge a simple interpretation of neuroimaging findings as pure neuronal activity, and necessitate a multivariate approach to assess the impact of different confounds. Most critical biological confounds include:

#### Baseline (psycho)physiological states

One of the most challenging aspects of designing functional neuroimaging studies is to establish and define a “baseline” state. In task-based fMRI, the problem is to some extent circumvented by the explicit design of a “resting” block, against which the activation in the task-blocks is compared. In RSfMRI, however, inferences are made based on the spatiotemporal features of the spontaneous hemodynamic fluctuations over time. Slight psychophysiological variations such as keeping eyes open or closed [Patriat et al., 2013], or diurnal phases [Hodkinson et al., 2014] may impact the reliability of functional network detection. It has been shown that circadian rhythm (with respect to the time of awakening) influences fluctuations in DMN and sensorimotor areas over the course of ten hours of wakefulness [Blautzik et al., 2013]. Interestingly, the functional connectivity of the posterior component of the DMN, and the insula have the highest interclass correlation coefficients if assessed from BOLD signals (but not from similar analysis of perfusion-weighted timeseries) [Jann et al., 2015]. It is not yet clear whether this BOLD-specific interclass correlation is explained by the consistency of physiological pulsations [Liu et al., 2013a], by the neuronal or cerebrovascular physiology [Liu, 2013] or by anatomy [Vigneau-Roy et al., 2014]. However by adding a control baseline condition (i.e., a pre-drug scan) and including an additional placebo session to the design, might make it more likely to tease apart such confounds.

The placebo effect on neuroimaging biomarkers in pharma-fMRI studies is not negligible [Meissner et al., 2011]. To add a placebo session can help identify drug-unrelated effects related to the experience of being in the scanner (e.g., fatigue, phobia, anticipation). However, variations in psychological states over time (during drug administration or placebo session) can contribute to the nonstationarity of the resting-state brain fluctuations (further discussed in “Reliability, Reproducibility”). It is therefore important to include repeated measurements of in both placebo and drug conditions in order to evaluate the influence of interindividual variations in brain’s psychopharmacodynamics.

#### Cardiopulmonary function

As will be discussed in “Structured Noise and Artifact Removal,” most fMRI studies treat respiration- or heart-related signals as nuisance factors and try to eliminate them, although some argue that by removing these variations information about neural correlates of proprioceptive functions or autonomic and metabolic control may be erroneously discarded [Bright and Murphy, 2015; Iacovella and Hasson, 2011; Vazquez et al., 2014].

Physiological correction in pharma-fMRI is a more complicated issue because of the direct and indirect effects of the CNS drugs on the autonomic nervous system. Respiration and heart rate are regulated by the interplay between brain areas that integrate autonomic, somatomotor and
propriocception, and by cerebrovascular autoregulation that adaptively maintains cerebral oxygen level via arterial inflow. Changes in the heart rate or respiration can be correlated with activation of the brainstem nuclei that control the autonomic system, or with neurovascular and neurochemical processes that fluctuate with the cardiac or respiratory rhythms, respectively. For instance, respiratory depression after opioidergic drugs causes hypercapnic conditions that trigger a strong vasodilatory response and create strong vascular reactivity, which in turn confounds the use of BOLD signal to detect neuronal responses [Pattinson et al., 2009]. Drugs that increase heart rate or blood pressure also increase pressure wave pulsatility in cerebral arteries, and may result in motion-related spurious effects in the proximity of major arteries [Dagli et al., 1999]. Global physiological responses of the cardiorespiratory system during different drug conditions likely give rise to signal changes that resemble a global change in CBF—which will be indistinguishable between different drug classes. Efforts to tease apart these mechanisms on phMRI signals continue [Faull et al., 2015; Mitsis et al., 2009; Pattinson et al., 2009], but combined BOLD/ASL acquisitions discussed in “Combined ASL/BOLD fMRI and Neurovascular Coupling” will further improve our understanding of these mechanisms.

Either way, neuronal fluctuations related to physiological factors are essential pharmacodynamic endpoints and must not be discarded as “noise.” Physiological noise correction schemes may drastically alter the statistical outcome of the drug effects on the brain [Khalili-Mahani et al., 2013]. Interestingly, the regions of precuneus and posterior cingulate cortex in the DMN seem to be most vulnerable to physiological effects especially in higher-level statistical comparisons [Khalili-Mahani et al., 2011]. However, regional susceptibility to physiological noise relates to the scale of drug-induced change in respiration and heart rate. For example, these effects are very significant in the morphine condition that causes strong respiratory effects, and non-significant in alcoholic condition in the same subjects [Khalili-Mahani et al., 2013]. The method chosen for physiological noise correction can also impact the extent of the statistical outcome. For example, the impact of time-series correction using derived respiration and cardiac variation regressors, or RETROICOR on final statistical outcome is lower than using averaged respiration rates in the highest level group analysis [Khalili-Mahani et al., 2013] (see Fig. 6). Unfortunately, many of existing pharmacological studies surveyed here do not report any physiological records (see Table I). However, a rigorous characterization of the physiological interactions with vascular effects of the drugs is essential and informative in understanding specific and nonspecific effects of the drug on neuroimaging biomarkers.

**Age and sex effects**

As Figure 7 shows, the age range (20–45, with the exception of three studies) and sample sex (male > female) are biased in the studies we reviewed, reflecting the challenging nature of experimental designs. In older adults, the study design must provision for how a particular compound interacts with other medications or concomitant health conditions. To include females would require controlling for endocrinological factors related to menstrual cycle, birth control or hormonal replacement therapy (in older women) [Comasco et al., 2014]. Yet, without expanding demographic representation of females and age ranges in pharma-fMRI studies, it remains a challenge to draw general conclusions about the CNS mechanisms of any drug. While challenging in humans, animal pharma-RSfMRI studies might illuminate the significance of these variables.

**Anatomical variability**

This survey illustrates a general neglect of the potential impact of anatomical variations on localizing drug effects. In particular, given that drugs reach the brain via the circulatory system, and given the high likelihood of cardio-pulmonary physiological responses to drugs, the impact of the morphology of the cerebrovascular tree and flow territories on functional topography of drug effects may not be a negligible confound.

Gross anatomical features include variables such as the shape and the size of certain brain structures, cortical surface anatomy and gyriﬁcation. Cao and colleagues have shown that anatomical variations related to the choice of anatomical parcellation schemes used for network representation of the brain) do impact the reliability of graphmetrics, although some local and global network properties are more robust to parcellation effects than other metrics [Cao et al., 2014].

Gross anatomical features also include configurations of the cerebrovascular tree and the white matter ﬁber tracts that underpin connectivity by “wiring” the brain. CNS drugs are transported into brain tissue from blood across the walls of capillaries or through CSF transportation into venous blood [Pardridge, 2012]. Variations in the cerebrovascular architecture are thus likely to inﬂuence variations in measured RSfMRI and ASL signals [Tak et al., 2014, 2015; Vigneau-Roy et al., 2014]. In fact, one of the major challenges in reproducing ASL results stems from between-subject variations in cervical anatomy that can alter model parameters used to quantify CBF [Aslan et al., 2010]. To what extent these model parameters vary with pharmacological stimulation, cerebrovascular anatomy or the layout of the arterial flow territories [Bokkers et al., 2011; Hartkamp et al., 2011] is not yet studied.

**Structured Noise and Artifact Removal**

**Head motion**

Rigid-body head motion artifacts, that is, those caused by moving the head during acquisition, deteriorate the quality of the MRI data. If the movement happens during
acquisition of a frame, the data becomes corrupted and must be discarded, but if motion happens between acquisition echoes, then it causes misalignment of frames and it can be corrected. The most common motion correction technique uses simple transformation (3 translation and 3 rotations, and maybe three stretches, using a standard cost minimizing function such as least square error) to align all frames of an EPI dataset with respect to an arbitrary frame of reference from the time series (usually the middle frame). This procedure often returns a matrix with an estimate of linear movement, stretch and rotation in a 3D space per each frame, or an estimate of excessive and artifactual signal spikes in adjacent frames. These motion parameters (and their derivatives) are often included as nuisance regressors, and included in models that estimate connectivity. Another approach is to “scrub” or “censor” frames that are characterized with excessive movement and to discard them out of the RSfMRI timeseries [Power et al., 2011], albeit with added temporal and spatial filtering and regression options [Carp, 2013; Power et al., 2014; Satterthwaite et al., 2013].

In an elegant study evaluating the impact of interactions between the temporal, spatial and spectral characteristics of motion and different preprocessing techniques, Satterthwaite et al. have demonstrated that different correction methods are not uniformly effective [Satterthwaite et al., 2013]. In fact, in a survey of various motion-correction methods, Power and colleagues have concluded that regression-based motion-corrections “represent cosmetic improvements rather than true correction of the data” [Power et al., 2014] and that there is no definitive answer to the best way motion effects can be mitigated [Power et al., 2015]. Methods using ICA to isolate motion components from the data [Griffanti et al., 2014; Kundu et al., 2012; Salimi-Khorshidi et al., 2014; Tohka et al., 2008] avoid breaking the temporal continuity of the data or creating inconsistent temporal degrees of freedom, which would be caused by scrubbing methods. But ICA-

---

**Figure 7.** Sample sizes and age ranges distribution in the surveyed studies.
denoising techniques depend either on subjective classification of the artifact components, or on automatic feature selection based on a priori assumptions about the pattern of motion artifacts [Pruim et al., 2015]. In a recent comparative analysis Pruim et al. have compared eight common motion correction strategies, and have concluded that ICA-AROMA was more effective in reducing motion artifacts across datasets in retaining signal of interest and improving reproducibility.

Although these corrective measures seem to improve the consistency of detecting the functional architecture of the brain, the correction residuals of these regressors are not “white,” and remain anatomically specific [Power et al., 2012; Van Dijk et al., 2012; Yan et al., 2013b]. In fact the problem of motion may be different in patients versus healthy controls [Kong et al., 2014; Wylie et al., 2014]. This raises concern for pharmacological studies, if the drug causes variations in movement patterns, for example, with sedatives and anti-tremor compounds that are likely to reduce movement as compared with placebo, or stimulants and hallucinogens that may increase it.

**Physiological artifacts**

Physiological signals are important biological confounds but they can give rise to artifacts. The simplest form of physiological artifact arises from arteriovascular pulsation correlated with the heart beating, bulk movement due to breathing, or even a movement of the imaging plane due to magnetic susceptibility artifacts resulting from breathing in the magnet. These artifacts are often dealt with in addition to motion, either by modeling a movement-related phase-shift in each EPI acquisition, combined with a canonical hemodynamic response function to respiration and heart rate [Birn et al., 2008b; Chang et al., 2009]; by using a proxy correction by assuming that the BOLD signal fluctuations in the deep WM and CSF encode non-neuronal variations in respiration and heart rate signals [Birn, 2012]; or by using dual-echo acquisition methods that can help separate true noise from biologically relevant signals [Bright and Murphy, 2013b]. To date, the majority of work examining the impact of physiological correction on resting-state fMRI has focused on improved consistency of the DMN [Marchitelli et al., 2016], although in some cases, the DMN and the respiration component identified from ICA may be overlapping [Birn et al., 2008a]. In fact, it has been shown that respiration-related changes in end-tidal CO₂ create anatomically specific patterns in many temporal (e.g., Insula) and medial brain areas (e.g., cingulate cortex) that are commonly studied in pharmacological studies [Peng et al., 2013; Wise et al., 2004b].

In more than 60% of studies surveyed here, heart and respiration rates are not measured or reported. In only half of the rest, these variations are used as nuisance factors to “clean” artifacts from the data. In only one of these studies, the impact of various noise removal techniques on the statistical outcome of drug effect on the brain has been reported [Khalili-Mahani et al., 2013]. This study shows that morphine doses that cause significant physiological response (in terms of respiratory depression) also cause significant changes in the topography of the group results—namely a significant reduction of the statistical significance of drug effect on the DMN. In this study, corrective methods that are applied at the level of individual RSfMRI preprocessing or DR (e.g., regressors corresponding to respiration or heart rate variations or retrospective image correction with RETROICOR and RVHRCOR), were not as impactful—even though their impact on within-subject BOLD variations were significant and consistent [Khalili-Mahani et al., 2013] (also see Fig. 5). These observations raise concern about the implications of unscrutinized physiological “noise” correction and their impact on interpretations of results.

**Global signal regression**

Global Signal Regression (GSR) aims to correct for combination noise arising from subject movement, physiological artifacts, as well as high frequency electronic noise, or amplitude drift [Power et al., 2014; Satterthwaite et al., 2013]. Similar to motion and physiological correction, there is also no consensus on whether this preprocessing step improves the results or gives rise to false positives and misinterpretation. The strongest argument against GSR is that it artificially shifts and zero-centers the distribution of correlations, thus giving rise to anti-correlated patterns “erroneously” interpreted as deactivation [Murphy et al., 2009; Weissenbacher et al., 2009]. It has also been shown that GSR can hinder analyses of inter-individual differences [Saad et al., 2012], bias the topography of networks in relation to motion parameters [Satterthwaite et al., 2013], and confound activity that is closely correlated with signal in the gray matter [Yan et al., 2013a], including spontaneous fluctuations in local field potentials induced by changes of behavioral states of monkeys [Scholvinck et al., 2010]. Although the mathematical argument against zero-centering holds, others argue that this process increases the detectability of physiologically meaningful phenomena from the cortex [Fox et al., 2009]. The impact of GSR on test-retest reliability of metrics other than functional connectivity is also contentious. It has been shown that GSR improves the reliability of spectral analysis (using Alff) [Yan et al., 2013a], but worsens REHO [Zuo et al., 2013], although the influences of GSR on REHO reliability seem to be complex, anatomically varying, and related with neuronal mechanisms that underlie eyes-closed or eyes-open states [Qi et al., 2015]. It has also been shown that GSR alters the topography of graph representation of the brain by altering the network thresholds [Schwarz and McGonigle, 2011]. The effect of GSR on graph properties and test–retest reliability is made further complex by the mathematical assumptions underlying graph computations, for example, partial correlation or Pearson correlation, although differences in terms of
improved reliability with and without GSR may be negligible [Liang et al., 2012]. A recent review indicates that GSR does not cause significant changes in degree, local and global efficiency, but lowers the reliability of clustering coefficient and assortivity [Andellini et al., 2015]. In presence of these uncertainties, newer methods advise performing post-hoc estimation of the extent to which GSR changes the analysis outcomes [Carbonell et al., 2014a]. In general, although there is no consensus about including GSR in preprocessing, existing evidence suggest the necessity of considering the full scope of anatomical and spectral characteristics correlated with GSR [Liang et al., 2012; Qing et al., 2015]. Given the repeated-measures design in most pharmacological studies here, it might be revealing to investigate the differences in the test outcomes with and without applying different preprocessing steps.

**Reliability, Reproducibility**

In pharmacological neuroimaging, biomarker test–retest reliability is critical and a determining factor in establishing a meaningful effect size. It is also the most challenging, because spontaneous brain oscillations are non-stationary. Reliability and reproducibility in pharma-RSfMRI is not well addressed yet. In one study involving pharmacological stimulation by ketamine, it was shown that reliable estimates of the pharmacodynamics in the ROIs were possible but only if nuisance variables such as motion and drift were well modeled [De Simoni et al., 2013]. Although an important first step, the conclusions of this study are not generalizable. In this section, we highlight the impact of non-stationarity, data acquisition and analytical parameters on test–retest reliability in RSfMRI studies.

**Non-stationary neural networks**

A major challenge in establishing a ground truth for RSfMRI metrics is the fact that resting-state functional networks can be non-stationary, i.e. exhibit time-varying functional connectivity patterns [Allen et al., 2014; Hutchison et al., 2013; Jones et al., 2012; Liu and Duyn, 2013; Messe et al., 2014]. Non-stationarity in the brain is not ubiquitous, and may vary depending on the mental state, network of interest, or the time window over which connectivity is assessed. Although mentation is an obvious source of non-stationarity in brain physiology [Barttfeld et al., 2015], it can also exist in the absence of conscious or cognitive states. For example, Hutchison et al. [2013] have observed non-stationary behavior in the resting-state oculomotor network of anesthetized macaques that are comparable to those observed in awake human subjects [Hutchison et al., 2013]. It has been suggested that this dynamic change in network topographies relates to an adaptive change of states, in order to balance information processing and metabolic expenditure of the brain [Zalesky et al., 2014]. Using mathematical modeling in both simulated and empirical data, Messe et al. [2014] have shown that anatomical connections (derived from DWI) drive the stationary dynamics of functional connectivity. These findings create a compelling case for exploring non-stationarity itself as a biomarker of disease [Jones et al., 2012], or as a pharmacological endpoint.

As will be discussed in “Opportunities and Future Directions,” re-analyzing existing pharma-RSfMRI data with attention to the non-stationary nature of the spontaneous brain fluctuations and dynamics of network modularity might provide interesting information about cerebral pharmacodynamics.

**BOLD RSfMRI test–retest reliability**

The problem of non-stationarity underpins challenges in test-retest reliability of the BOLD response. Moderate to high reliability is observed in seed-based or NOI-based analysis; however, the degree of reliability varies between networks suggesting that some networks are more susceptible to state changes in acquisition or (psycho)physiological [Birn et al., 2013; Jann et al., 2015; Shehzad et al., 2009]. REHO seems to offer high test–retest reliability but is also sensitive to motion, global signal, scan duration and anatomical variations, thus can drastically change with preprocessing options [Zuo et al., 2013]. Moderate to high intra- and inter-session test–retest reliability of (f)ALFF has been shown although reliability varies in different brain regions, leaving the question of the impact of variations in mental states on reliability assessments [Zuo et al., 2010b]. Dual regression analysis using NOIs, seems to produce more reliable and reproducible results than seed-based analysis [Schultz et al., 2014; Zuo et al., 2010a], however the reproducibility of results depend on which set of networks are included in the analysis [Schultz et al., 2014], and preprocessing options or physiological covariates can change the configuration of certain networks [Khalili-Mahani et al., 2013]. The reliability of graph metrics is still under investigation. A systematic review of graph metrics failed to make definitive conclusions regarding the best technique, due to the heterogeneity of study designs and analytical choices [Welton et al., 2015]. Two studies [Braun et al., 2012; Cao et al., 2014] indicated that graph metrics such as path length, global efficiency, assortativity and modularity have higher test–retest reliability (0.57 < ICC’s < 0.75) than clustering coefficient, local efficiency and degree. The consistency of several brain networks that emerge from ICA has been well established [Damoiseaux et al., 2006; Wisner et al., 2013; Zuo et al., 2010a], but structured noise, and physiological and motion artifacts diminish the reliability of component detection [Zuo et al., 2010a]. Also, inconsistencies in dimensionality of ICA (e.g., number of components, and component ordering) impact the reliability of individual [Esposito and Goebel, 2011] and group [Abou-Elseoud et al., 2010] ICA. A relatively reliable group-ICA does not guarantee the reliability of the same individual ICA.
Lower individual reliability is likely to impact the reliability of the group inference testing as well, and therefore interpretation of effects. Several methods such as ICASSO [Himberg and Hyvarinen, 2003], RELICA [Artoni et al., 2014] and FOCIS [Wang and Li, 2014] have been proposed to help identify the most reliable independent components, however to automate the selection of functionally relevant components from spurious networks remains challenging. Interestingly, the impact of post-processing noise regression on group level statistics varies between different biomarkers [Yan et al., 2013a].

Acquisition time is an important factor in test-retest reliability. Gonzalez-Castillo et al. [2014] have conducted a series of tests to investigate the impact of scan duration and window size on reliability of functional networks, both at the individual and group levels. They found that the primary sensory-motor network was the most stable network across different scan time and analytical windows, compared with areas involved in higher cognitive processing. Tomasi et al. have recently shown that non-stationarity affects various RSfMRI metrics differently [Tomasi et al., 2016b]. For example, they showed that functional connectivity density (FCD, a data-driven graph theory metric that quantifies the local degree, the size of the local network cluster functionally connected to each brain network node) was more accurate than sICA or seed-based connectivity, but that accuracy for each metric varied with acquisition time, that is, sICA relied on longer scans (>12 min) to achieve the same accuracy as FCD (7 min).

Reliability of different RSfMRI metrics can vary depending on the mathematical description of the biomarker, which hinge on various factors including data acquisition parameters, preprocessing and statistical approaches, as well as different approaches to establishing reliability (e.g., interclass correlations versus coefficient of variation). These complexities make it difficult to be conclusive yet but encourage adopting standardized protocols that will enable us to compare sensitivity, accuracy, and reliability of various metrics toward establishing a practical guideline.

**ASL test-retest reliability**

Because ASL methods can provide a quantitative measure of cerebral perfusion, it is easier to evaluate their reliability. Consistency of CBF estimation with background-suppressed pCASL has been established in multi-center and multi-acquisition reproducibility studies [Gevers et al., 2011; Vidorreta et al., 2013]. Inter-session, intra-session and inter-scanner reproducibility across different vendors suggests that normalizing acquisition parameters on different machines yields stable measurements of the gray matter perfusion. However, in presence of differences in acquisitions sequences, spatial differences caused by different smoothing behavior of the readout module become problematic [Mutsaerts et al., 2014; Mutsaerts, 2015; Vidorreta et al., 2013].

A major challenge in reproducing ASL results stems from between-subject variations in cervical anatomy that can alter model parameters used to quantify CBF. The main limiting factor in between-examination and -subject variability is probably differences in labeling efficiency [Aslan et al., 2010]. Labeling efficiency in pCASL is dependent on local off-resonance effects, blood velocity as well as the angle of the artery with respect to the labeling plane [Dai et al., 2008]. Variations in labeling efficiency differences can be minimized by employing a pre-scan [Jung et al., 2010] or by performing additional shimming of the labeling region. Finally, during post-processing normalization by average whole brain CBF can partially correct for variations in labeling efficiency.

Another factor affecting the accuracy of CBF quantification by ASL is ATT (see “Arterial Transit Time”). The common model employed to quantify CBF assumes that all labeled blood has reached the imaging volume. Incomplete delivery of label would lead to underestimation of CBF. Furthermore, the loss of label due to longitudinal relaxation (T1) depends on whether the label is located in blood where it will decay with the T1 of arterial blood (~1,650 ms), or whether the label is in tissue where it will decay with the T1 of tissue (~1,200 ms). Shorter arterial transit times will often be accompanied with earlier arrival in tissue, and therefore faster decay of label. To what extent these model parameters can vary with pharmacological experiments, cerebrovascular anatomy or the layout of the arterial flow territories [Bokkers et al., 2011; Hartkamp et al., 2011] is not yet well understood. As discussed in “Arterial Spin Labeling and Cerebral Perfusion,” ASL methods are best suited for crossover designs where state-dependent variations in baseline cerebral perfusion, or regional heterogeneities in perfusion caused by drug can serve as surrogate markers of neuronal activity.

**Statistical Analysis**

Besides data acquisition, preprocessing protocols and the biomarker type, reliability depends on the criteria of statistical analyses. Pharmacological studies, whether exploratory (i.e., finger printing and probing experiment) or intended for clinical trials, demand establishing reliable statistical criteria to assess interpretable effectiveness of a given intervention. Existing statistical modeling approaches and toolboxes available for the statistical analysis of RSfMRI and ASL data are by and large inherited from task-based fMRI. As such, there are limitations in terms of estimating the effect size and statistical modeling, which we briefly discuss here.

**Effect size estimation**

Three main components are involved in the estimation of the statistical power: (1) the expected effect size, (2) the variability of the effect size and (3) the sample size of the
study. To establish an a priori effect size is one of the most critical aspects of clinical pharmacology for making go-no go decisions. In task-fMRI, the percentage of the change in BOLD signal is estimated by fitting a canonical hemodynamic response function to epochs of rest and activation, at the subject level. As such it is possible to compute the effect size as a voxel-wise averaged percentage of change. Usually, a 2% signal change from the no-task condition reflects a task-induced neuronal effect. Effect size can also be easily estimated in ASL studies, as it is possible to quantify the percentage of change in cerebral blood flow. In RSfMRI, effect size is estimated in terms of connectivity (z-scores or correlation coefficients) or some graph metric, which are dependent on meaningful thresholding of connectivity or coherence metrics. Given the dynamic nature of drug effects on the brain and thus on RSfMRI fluctuations, interpretation of an effect depends not only on the magnitude of change (e.g., pre- vs. post-drug, placebo versus drug), but also on the dynamics of change (increases and decreases) between different timepoints. Furthermore, as discussed above, the direction of observed effects do not represent absolute neurobiological phenomena, but relative changes which can vary with variations in global or regional corrections and noise thresholds. For this reason, it is essential to interpret results with attention to the mathematical underpinnings of each biomarker, and in the least plotting the temporal profile of data in a given region during the course of drug administration in relation to placebo—instead of just relying on test statistics and average activation maps.

In neuroimaging studies, power analysis may become possible by collecting information from one ROI, but the choice of the ROI runs the risk of biasing the estimated effect size [Mumford, 2012]. It is also possible to select multiple ROIs, although there are no generally established guidelines to account for multiple comparisons in this case. A major complication in power analysis for any fMRI experiments is that variability comes (in a hierarchical way) from several sources: intra-run variability that reflects noise within auto-correlated time series of each fMRI run; intra-subject variability that comes from repeated runs within the same subject; and between-subjects variability within a population. To this complicated picture, add the complexity of central and peripheral pharmacodynamic effects over time, and over different regions, which need to be accounted in power analysis as well.

**Statistical modeling**

There are three existing limitations in statistical modeling for pharmacological imaging experiments. First, drugs exert non-linear and spatially heterogeneous effects (related to a combination of neurovascular factors or chemo-architecture [Shulman and Rothman, 1998]). What covariates to include in an analysis can impact the topography of the results significantly [Khalili-Mahani et al., 2012, 2013; Niesters et al., 2012]. We have shown that the relations between CBF and connectivity measures can vary from region to region, depending on what explanatory variables are included in the model [Khalili-Mahani et al., 2013, 2014]. Secondly, pharmacological experiments ideally depend on integration of repeated measurements from different modalities, for example BOLD-related connectivity maps and relative CBF maps, which are correlated but have different smoothing characteristics. Finally, and importantly, repeated measures analysis is essential to most pharmacological experiments concerned with fingerprinting, where the minimum number of scans is four (one pre-, and one post drug scan per placebo and drug session), thus controlling for within-subject correlations is important.

The majority of neuroimaging reports surveyed here rely on voxel-wise T-tests (between group or between time), (m)AN(c)OVA or multilevel GLM with mixed effects (time, group, drug, nuisance, behavior) analyses, often using standard software packages [Beckmann et al., 2003; Chen et al., 2012; Friston et al., 2005; Worsley et al., 2002]. Methods to address the first two problems are explored in the context of multivariate analysis and machine learning, which will be discussed later in this section. The third problem is addressed in newer methods such as multi-scale adaptive generalized estimating equation (MA-GEE) [Li et al., 2013] or Sandwich Estimator [Guillaume et al., 2014], which are more suitable to inference testing with repeated, longitudinal measurements. However, to our knowledge, these methods have not been used by any of the studies in this survey. A re-analysis of the data using these methods will be informative.

**Significance criteria**

Neuroimaging studies create massive amounts of data, and rely on special adjustments for addressing the problem of multiple comparisons. The issue of multiple comparisons is well addressed in neuroimaging statistics. Most current fMRI studies surveyed here rely on cluster-wise correction of family-wise errors. In this approach voxels satisfying a nominal threshold (e.g., t-value > 1.7, to yield uncorrected threshold of 0.05, on assumption of a normally distributed t-test) are selected, then a cluster-level extent threshold, measured in units of contiguous voxels over resolution elements (resels, which depend on the search volume and the FWHM of the smoothing kernel) is determined based on the estimated distribution of cluster sizes under the null hypothesis of no activation to correct for family-wise errors. The sampling distribution of the largest null cluster size can be estimated using random field theory [Worsley et al., 1992], Monte Carlo simulation [Forman et al., 1995], or nonparametric methods [Nichols and Holmes, 2002]. To avoid this arbitrary selection of the initial threshold, Smith and Nichols [2009] have proposed a threshold-free-cluster-estimation (TFCE) method, which considers the entire statistical data in order to identify voxels that, judged by the magnitude of the signal and its
spatial distribution, cluster together [Smith and Nichols, 2009]. Whereas these sets of techniques try to minimize the probability of false positives), another method, false discovery rate (FDR) provides more statistical power by setting thresholds based on tolerance for false positives, by ranking the probability of all observations and arbitrarily rejecting a percentage of those [Genovese et al., 2002]. Whether cluster- or FDR-based correction methods are stringent or reliable enough has recently come under scrutiny [Eklund et al., 2016; Woo et al., 2014]. A recent analysis of 499 RSfMRI datasets has estimated that standard cluster-based thresholding methods available in popular analysis packages (FSL, AFNI and SPM) are prone to inflating false positives [Eklund et al., 2016] and have proposed permutation testing to avoid errors arising from unmet assumptions about smoothness and normal distribution of the data.

Permutation testing provides a more stringent approach to determining statistical significance based on consistent estimates of means and variances for central and non-central t-tests [Nichols and Holmes, 2002; Zhou et al., 2014]. This is particularly important in pharmacological studies, which have small samples and thus may not satisfy the assumptions of normal distribution at the level of group analysis. Permutation testing is also more robust to cluster-size changes due to non-stationarity in fMRI signals, whether using RFT methods [Hayasaka et al., 2004] or TFCE [Salimi-Khorshidi et al., 2011] to establish statistical significance. Multi-level permutation testing will also give more stringent control of false positives [Winkler et al., 2015] in repeated measures longitudinal analysis, which would be necessary for most pharmacological experiments.

Multivariate analysis and machine learning

Univariate analyses (discussed above) aim to detect if and how different brain regions are affected by a given stimulus (regression), or by other independent variables (factors or covariate), while accounting for the problem of multiple comparisons. Multimodal data collection lends to more sophisticated multivariate analysis approaches. In the simplest implementation, multivariate models extend the GLM to allow for a single analysis with multiple dependent variables (as opposed to running several regressions on a single dependent variable in univariate analysis). As such a single analysis provides multiple levels of inference and a more suitable design for complex research such as pharmacoinaging.

Supervised Machine Learning (ML) techniques are increasingly important for multivariate analysis, and predictive pattern recognition. These methods aim to identify optimal mappings between the multivariate brain signals and external variables, such as symptom levels or drug conditions. ML algorithms might utilize any number of data features, such as network connectivity matrices, seed or dual regression maps, variance or REHO measures, or graph theoretical characterizations. These mappings can produce prediction accuracies in new data that greatly exceed what is possible from any individual feature of the data, and can reveal the modulation of subtle, spatially extended features of neural activity by pharmacological agents that would otherwise be missed by univariate analyses. As such ML techniques are likely to be crucial for potential translational applications of pharmacological imaging such as the identification of disease states in patients with limited ability to communicate [Wager, 2013], the assessment of pharmaceutical candidates for signatures of pharmacological efficacy [Doyle et al., 2013; Duff et al., 2015], or the characterization of the timecourse of drug action in individual subjects [Paloyelis et al., 2016].

Common ML pattern recognition techniques include support vector machine (SVM) and Gaussian process classification (GPC). SVM aims to classify individual observations (e.g., connectivity maps) into distinct groups or classes based on maximizing the margin between classes in a high-dimensional space (i.e., multivariate data). This classification depends on a pre-defined training data, which is obtained by exhaustive comparison of data from two groups (e.g., patient and control, or pre and post drug). This classifier is then used to identify to which group data from a new individual maps [Orru et al., 2012]. In contrast to SVM, where the certainty of the prediction is tested against the support vector, GPCs are based on a probabilistic distribution of functions which represent the training data. As such GPCs are suitable for providing a probabilistic prediction (as opposed to binary prediction in SVM) of states such as pain [Marquand et al., 2010]. Differences in SVM and GPC have implications for when to apply which. For example, linear SVMs discriminate according to a subset of samples (training set) that form the separating support vector. As such SVMs are robust to outliers and perform reasonably well with the typically low sample sizes of pharma-fMRI studies. However, SVMs are most suitable to binary discrimination between two groups, and heterogeneous data may require more complex discrimination functions which can be difficult to define with SVMs. Because GPC utilizes the full sample distribution for predictions it allows using more complex decision functions and probabilistic outcomes, but these functions are more challenging to estimate than support vectors and, due to its probabilistic nature, GPC is more affected by outliers.

To date, Monti et al. [2013] have used network connectivity matrices as inputs to SVMs in an exploration of states associated with propofol anesthesia. In their study, connectivity matrices could reliably discriminate wakefulness from periods of sedation and unconsciousness. Similarly, Sripada et al. [2013a] trained SVMs to discriminate effects of methylphenidate from placebo scans using network connectivity matrices generated from 1,080 ROIs. The whole-brain data was able to reliably identify the
effects of methylphenidate. The results of an initial feature selection stage were used to identify predictive changes as being associated with reductions in coupling within a number of resting-state networks (RSNs), and changes in the coupling of the default mode network (DMN) with other RSNs.

Classifications algorithms can also be used to characterize similarity. Using GPC, Doyle et al. [2013] first established the predictive probability of BOLD signal change in response to ketamine based on discriminating placebo—saline and ketamine—placebo) and then showed that pretreatment with lamotrigine and risperidone attenuated the effects of ketamine, making resting-state ketamine—lamotrigine and ketamine—risperidone conditions more difficult to distinguish from placebo.

GPC has also been used to explore the dynamics of oxytocin action on the spatiotemporal profiles of brain activity, by examining changes in the sensitivity of connectivity-based classifiers across an administration period [Paloyelis et al., 2016].

However, despite their strengths, all ML techniques have limitations and tradeoffs, and are not always the appropriate tool. Due to the multivariate nature of ML algorithms, it can be difficult to determine the nature of the signals driving predictive accuracy. ML algorithms may take advantage of subtle modulations of brain activity for prediction, but may also exacerbate the influence of subtle confounds. Choosing and tuning a classification algorithm can be complex, particularly with the low sample numbers of imaging, which make selection of parameters via approaches such as cross-validation unreliable. The diversity of options for ML, and lack of standard software for neuroimaging applications, produce additional challenges for reproducibility. Also, multivariate analysis depends on complete sample and is not amenable to missing data. Therefore, in many cases, univariate analysis would be more appropriate.

### Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling

The ultimate goal of pharmacological neuroimaging is to establish a relation between drug dose, and a meaningful effect in neuronal activity that helps estimate the efficacy of the treatment. PK/PD modeling (which encompasses limitations discussed in “Statistical Analysis”) involves estimating piecewise-linear transfer functions that describe the nonlinear profile of the drug uptake and washout. A mathematical description of a predictive transfer function is obtained from solving a partial differential equation that estimates pharmacokinetics model coefficients, that is, the time course of drug action at different doses in different compartments (e.g., gut, liver, blood, target tissue) in relation to different pharmacodynamic phenomena (i.e., the behavioral or symptomatic endophenotypes for which the drug is designed). Such predictive models are important for reproducing results, or for identifying deviations from the model in clinical populations. Within this mathematical framework, differences between subjects (e.g., in terms of age, gender, illness severity and comorbidities, medications, etc.) should also be accounted for.

PK/PD modeling has contributed significantly to a better understanding of drug effects (and their variability) in clinical studies, to the translation of drug effects between species or populations, and to the optimization of clinical trial designs. A clear PK/PD-relationship also offers reliable information on which part of an observed effect is due to pharmacological activity—in addition to other sources of variation. For these reasons, the identification of PK/PD models that predict the relation between the rates of drug distribution, absorption, metabolism and excretion (pharmacokinetics) and changes of MRI parameters, will provide strong support for the significance of neuropharmacological imaging.

PK/PD modeling is a challenging method in general and even more so in fMRI experiments. The CNS effects of drugs are highly dependent on the concentrations of the pharmacologically active moiety at the action site. The time to reach an effect, the concentration at the site of action, and hence the intensity of the effect, are determined by the pharmacokinetic properties of a drug. The onset and the size of the effect can vary considerably among individuals and over time, depending on differences in absorption (related to formulation, mode of administration and influence of meals), metabolism to active or inactive moieties, and excretion and distribution of the compound. Penetration of the brain is regulated by the blood–brain barrier (BBB), which can limit the extent and rate of distribution of compounds into the CNS. In humans, it is almost always impossible to measure the concentrations of the active compounds (which can also be metabolites) at the action sites in the brain. In most cases, drug concentrations are measured in blood serum or plasma. The anatomy and density of blood vessels that deliver the drug to the BBB are likely to introduce variations in that measure as well.

The consequence of this complex cascade of pharmacokinetic and pharmacodynamic events is that there is nearly always a time lag between administration of the drug, its binding to its target, and the measurement of CNS effects. This can vary from seconds or minutes for intravenously injected drugs that penetrate rapidly into the brain and affect cell membrane receptors, to hours for compounds that are slowly absorbed or induce protein formation, and even longer for medicines that influence cell growth. Moreover, the relationships between concentrations and effects can change over time, by development of tolerance or by accumulation of lipophilic active metabolites in the effect compartment. Finally, most effects require a minimal level of drug exposure, and are limited to a maximum tolerable dose. As a consequence, the relationships between blood concentrations and effects are usually not linear, but can often be adequately described by a more complex...
OPPORTUNITIES AND FUTURE DIRECTIONS

The field of RSfMRI is relatively new, yet rapidly evolving. Many of the limitations mentioned above, such as optimal pre-processing and data cleaning, biomarker accuracy and reliability, and the best statistical modeling and effect size estimation methods, are being actively investigated. So far, we have discussed existing methods that can be used for studying brain chemistry and have provided examples to illustrate how pharmacological experiments can help interpretability of RSfMRI studies in general. There are still unexplored opportunities provided by the current state-of-the-art data acquisition and analysis strategies, which will guide future pharmacological studies.

Data-Sharing and Meta-Analysis of the Existing Data

In many areas of clinical neuroimaging research, collaborative research takes place within a common framework for data harmonization, sharing and standardized analysis [Das et al., 2016; Petersen et al., 2010; Schmaal et al., 2016; Thyrreau et al., 2012; Zijdenbos et al., 2002]. In 2007, the Radiologic Society of North America (RSNA) organized the Quantitative Imaging Biomarker Alliance (QIBA) to develop standards for reducing variability across instruments and analysis, and they have now provided guidelines for uniformed terminology, statistical approach and performance measure [Kessler et al., 2015]. Pharmacomaging researchers may provision for more impactful research through data-sharing and data-mining. In fact, FDA’s Critical Path Initiative [2004] emphasizes the importance of using technology in drug discovery process. Since then, initiatives such as the Open Pharmacological Concepts Triple Store (Open PHACTS) have aimed to create a pharmacological data-mining platform to address drug discovery problems including target identification, dose optimization, toxicology and drug-drug interaction [Goldmann et al., 2014; Williams et al., 2012]. Existing neuroinformatics platforms for collaborative neuroimaging data-sharing and data-mining [Das et al., 2011; Glatard et al., 2013, 2015; Sherif et al., 2014] can be adapted to advance reliability and reproducibility of pharmacological trials.

With few exceptions of studies conducted in the same center, the studies surveyed here are very heterogeneous in experimental and analytical designs and because there are no standards for modeling and defining a meaningful effect size yet, it is difficult to perform a meta-analyses and arrive at a conclusive interpretation of the sensitivity and reliability of a given biomarker to a given neurobiological process. Nevertheless, there are many commonalities in the existing datasets from multiple centers that it is plausible to aim for a future data-mining exploration. The majority of pharmacological experiments reviewed here have collected data from healthy young men (Fig. 7) and T2*W images are collected in more than 75% of these studies. Two thirds of research objectives of studies reviewed are drug fingerprinting (33%) and probing specific neurotransmitter systems (33%), with a majority also

mathematical function, incorporating measures of baseline activity, minimal and maximal effect and (cumulative) time delay.

The earlier phfMRI experiments (to remind, these are experiments where the drug serves as a stimulus and the hemodynamic response is estimated from variations in the drug dose) used pharmacokinetic modeling to estimate regional activations, for example with nicotine [Bloom et al., 1999; Stein et al., 1998], cocaine [Kufahl et al., 2005], remifentanil [Leppa et al., 2006], morphine [Becerra et al., 2006], citalopram [McKie et al., 2005], m-Chlorophenylpiperazine (mCPP) and Mirtazapine [McKie et al., 2011] and ketamine [Deakin et al., 2008]. In these studies, duration of acquisitions was short and consistent with peak effects, for example, 7 minutes for remifentanil [Leppa et al., 2006], 8 [Deakin et al., 2008] and 10 minutes with ketamine [De Simoni et al., 2013], and 25–30 minutes for morphine [Becerra et al., 2006] and between 30 and 60 minutes for the serotonergic drugs citalopram and mPCC [McKie et al., 2005, 2011]. Pharmacokinetic modeling enables dose normalization in pharma-RSfMRI studies and preliminary attempts have been made to illustrate a link between plasma drug concentrations of drugs such as ketamine [De Simoni et al., 2013; Doyle et al., 2013; Khalili-Mahani et al., 2015], THC [Klumpers et al., 2012], opioi
dergic drugs [Becerra et al., 2006, 2013; Khalili-Mahani et al., 2012; Wise et al., 2004a] and alcohol [Esposito et al., 2010; Khalili-Mahani et al., 2012], and the amplitude of change in selective brain regions significantly affected by these drugs. However, no formal PK/PD models for predicting a cerebral dose-response have been reported yet. There are two main reasons for this: one is the paucity of studies with detailed time profiles of drug concentrations and effects, and the second is the lack of simple MRI readouts.

Current attempts at PK modeling have been further limited by either fitting a canonical PK model to the brain data [Bloom et al., 1999; Doyle et al., 2013; Stein et al., 1998], or by using a summarized readout (e.g., global signal change or ROI signals) to identify and validate a model [De Simoni et al., 2013]. As statistical parametric maps of the chemoarchitecture of the brain are being developed [Zilles et al., 2002; Zilles et al., 2004; Zilles and Amunts, 2009], to impose a single model across the entire brain anatomy (e.g., in calibrated BOLD/ASL modeling of neurovascular coupling) becomes questionable. However, with evidence from fingerprinting dose-response, and probing experiments it becomes feasible to integrate data from different modalities (e.g., cortical morphology, white matter tractography, and cerebrovascular anatomy) and apply advanced biomathematical modeling in a similar fashion as proposed for PET [Gunn et al., 2011]. (See section “Contributions From PET” for more details.)
using functional connectivity metrics obtained from seed, ICA, clustering or graph analyses (>53%).

To pool, harmonize and (pre-)process common data through a standardized pipeline, serve the objectives of an exploratory model-free mega-analysis which may shed light on current uncertainties about meaningful effect sizes and analytical and biological factors that differentiate the sensitivity of various metrics and models. This approach could increase the clinical impact of pharmacological studies. For example, different groups have studied pharmacological probing of the dopaminergic, opioidergic, GABAergic and glutamatergic systems using the same scanning parameters. Data processing parameters (e.g., choice of filters, blurring kernels and inclusion of common nuisance regressors) and statistical analysis criteria (e.g., standards for thresholding to assess statistical significance or inclusion of common covariates such as physiological rates or voxel-based anatomical regressors in the group-level models) can be established independent of drug class. Re-analyzing these data with similar preprocessing options and statistical modeling choices will make direct comparison of results possible. For instance, Kleinloog et al. [2015] combined 323 identically-acquired RSfMRI samples from four different pharmacological challenges (ethanol, morphine, Δ(9)-tetrahydrocannabinol and ketamine) to examine the relation between the severity of drug induced psychomimetic effects and functional connectivity and showed that the subjective effect of perception was the only psychomimetic factor that was commonly correlated with the connectivity of the posterior cingulate cortex and precentral gyrus with the sensorimotor network [Kleinloog et al., 2015].

The issue of non-stationarity and dynamics of network hierarchy and modularity is poorly studied, and a joint analysis of data under different drugs may help better characterize which neural networks are stationary and which vary according to drug-dependent dynamics.

**Standardizing Multivariate Data Acquisition**

Pharmacological fMRI experiments are expensive and necessitate highly controlled monitoring setups, which generally make the datasets richer than non-pharma RSfMRI studies. With the current drive for generating Open Science and data-sharing platforms, it is important to provision for a longer life cycle for the data, by adhering to operational guidelines that help minimize data acquisition errors [Schwarz et al., 2011a,b] and by developing community standards for data acquisition in such a way as to maximize the amount of data that can be gathered from a given study without compromising the main study objectives. Given the cost and practical difficulties associated with a pharmacological experiment, the benefits of collecting comprehensive datasets outweigh the cost of adding scan time. Furthermore, with growing availability of pharma-RSfMRI data, and with unified and standardized analytical approaches to biomarker development and validation, multivariate data analysis, and machine learning pattern recognition are expected to become the paradigm of choice for response prediction and drug-effect classification, which are critical objectives for CNS drug research.

We have summarized the minimum recommended requirements of a standard pharmacological imaging experiment in Table II, and have listed all basic and advances design, acquisition and analysis options in Table III, which can serve as a guideline.

As discussed in “Challenges and Limitations,” RSfMRI signals are highly sensitive to psycophysiological states. Randomized and placebo controlled experiments that include repeated RSfMRI and ASL measurements help increase the power of the study and provide a picture of the dynamics of drug action in the brain during the pre-drug baseline, the peak of drug dose, and the washout, if the drug is fast acting. Monitoring cardiac and respiration rates is critical for data interpretation and noise removal. Repeated psychosomatic readouts (e.g., nausea, weakness, sleepiness) and psychometric assessments (e.g., alertness, hallucination, calmness, anxiety), as well as serum samples from which to measure plasma concentrations of the drug, certain hormones, proteins and metabolites, will provide a richer parameter set for machine learning or PK/PD modeling. Furthermore, Including MR angiography or venography scans can help characterize the contribution of vascular factors to resting-state functional variations and to learn how neurovascular features such as capillary density, tissue vascularization and arterial flow territories factor into the efficacy of drug transportation to its site of action. Also, since functional and structural connectivity are closely linked [Greicius et al., 2009], and disease-related changes in white matter fiber connections might influence resting-state functional biomarkers [Wang et al., 2015], including diffusion weighted tractography further enriches any phMRI dataset. More recent methods such as ultra-fast fMRI [Feinberg et al., 2010], multi-echo fMRI [Kundu et al., 2013], quantitative fMRI [Christen et al., 2013], and vessel-encoded [Zhang et al., 2016] or time-encoded [Teeuwisse et al., 2014] pCASL have not been tested in pharmacological studies yet, but are likely to improve the temporal resolution of data and circumvent some errors related to physiological or motion artifacts. Importantly, to acquire fMRI data at higher temporal resolution would be important for exploring non-stationarity in spontaneous BOLD fluctuations—which can be studied in windows of 40–100 s [Leonardi and Van De Ville, 2015; Zalesky and Breakspear, 2015]. Such datasets provide a better opportunity to study the dynamics of functional connectivity toward a better understanding of the neural mechanisms of brain adaptation to intervention or disease [e.g., Bassett et al., 2011; Cole et al., 2014; Jones et al., 2012].
Of course, collecting multimodal data causes subject fatigue and increases the risks of excessive movement and discontinuation. A well-designed pharmacological experiment is usually conducted in two independent sessions (one for drug and one for sham placebo). In each session, one set of anatomical scans (TIW, MRA and DTI) are acquired—usually at the beginning of each scanning session to help localize the field of view for RSfMRIs. Optimal acquisition time for detecting reliable functional networks is between 7 and 14 min, albeit dependent on the metric of interest [Anderson et al., 2011; Gonzalez-Castillo et al., 2014; Tomasi et al., 2016b], and a reliable background suppressed whole-brain pCASL (30–40 pairs) can be acquired in less than 5 min; thus each repetition of a post-drug RSfMRI can be done in less than 20 min which is tolerable. In drug fingerprinting studies conducted at Leiden University Medical Centre that run up to 8 hours, the scanner areas are designed in such a way to allow rolling study participants in and out of the scanner (preferably in supine position) at given intervals. Psychometric and bio-specimen data are thus collected outside the scanner in a dedicated private area. Such procedures are made possible by scanners that are equipped with a smart scout protocol (e.g., SMART in Philips or AutoAlign in Siemens scanners), including the scanner used in the Leiden studies, that help automatically reposition the field of view (FOV) in subsequent scans to facilitate breaking up scanning sessions when conducting repeated measurements. To provision for a comfortable scanning environment will increase participant compliance with longer scanning protocols accommodating multi-modal data acquisition. 

**Contributions from PET**

The arguments in favor of MRI versus PET, for mapping neuronal response to pharmacological interventions have already been presented at the very beginning of this article. Although BOLD-fMRI effects are by and large indirect and nonspecific (confounding neuronal, metabolic, and hemodynamic responses), the convergence between RSfMRI biomarkers and metabolic activity detected by PET [Aiello et al., 2015; Passow et al., 2015; Soddu et al., 2016; Tomasi et al., 2013, 2016a; Toussaint et al., 2012] justifies substitution of some PET experiments with fMRI for localizing brain activity. However, in pharmacological applications, the value of PET rests with its exquisite sensitivity to radioactivity concentration variations, which makes it capable of measuring interactions of PET radiotracers with different molecular targets in the physiologic range. To this day, no other non-invasive imaging approach has been able to obtain the type of molecular information provide by PET, and none is expected to do so in the short to medium term. Recent advanced in PET/ MRI imaging are thus critical to advancing pharma-fMRI research.
### TABLE III. Guidelines for design and analysis of pharmacological RSfMRI studies

<table>
<thead>
<tr>
<th>Design Considerations</th>
<th>Minimum standards</th>
<th>Advanced state-of-the-art</th>
<th>Section in text</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacokinetics</strong></td>
<td>10-min RSfMRIs, repeated as needed to cover the entire duration of drug administration and washout</td>
<td>Fast RSfMRI</td>
<td>Experimental Objectives and Clinical Relevance</td>
</tr>
<tr>
<td>Baselines and Control</td>
<td>Placebo Control</td>
<td>Pre-drug, post-washout scans in both drug session and placebo session</td>
<td>Biological Confounds</td>
</tr>
<tr>
<td>Health condition</td>
<td>Full screening of prescriptions as well as medical screening of physiological and metabolic state</td>
<td></td>
<td>Biological Confounds</td>
</tr>
<tr>
<td>Mode of administrations</td>
<td>Single or multi-dose oral</td>
<td>PK-controlled infusion</td>
<td>Table I</td>
</tr>
<tr>
<td>MRI Acquisition</td>
<td>T1W anatomical MRI</td>
<td>TOF-MRA</td>
<td>Biological Confounds, Standardizing Multivariate Data Acquisition</td>
</tr>
<tr>
<td>Functional fMRI</td>
<td>T2*w EPI (TR/TE = 2,000/30), 5–10 min</td>
<td>Ultrafast T2*, dual-echo BOLD/ASL</td>
<td>Pharmacological fMRI (Pharma-fMRI), Spontaneous BOLD Signal Fluctuations and Functional Networks, Standardizing Multivariate Data Acquisition</td>
</tr>
<tr>
<td>Blood flow</td>
<td>pCASL</td>
<td>VS-ASL, TE-ASL</td>
<td>Arterial Spin Labeling and Cerebral Perfusion</td>
</tr>
<tr>
<td>Myelination</td>
<td>DWI</td>
<td></td>
<td>Standardizing Multivariate Data Acquisition</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>Seed-based or NOI-based networks</td>
<td>Dynamic FC, hierarchical clusters</td>
<td>Spontaneous BOLD Signal Fluctuations and Functional Networks and Reliability, Reproducibility</td>
</tr>
<tr>
<td>ICA</td>
<td>sICA, tICA, gICA</td>
<td>ICASSO, RELICA</td>
<td>Spontaneous BOLD Signal Fluctuations and Functional Networks and Reliability, Reproducibility</td>
</tr>
<tr>
<td>Graph</td>
<td>Centrality, efficiency, small worldness, path length</td>
<td>Dynamic modularity, assortativity</td>
<td>Spontaneous BOLD Signal Fluctuations and Functional Networks, Dose/Response in Anesthesiology, and Reliability, Reproducibility</td>
</tr>
<tr>
<td>spatial coherence</td>
<td>REHO</td>
<td></td>
<td>Spontaneous BOLD Signal Fluctuations and Functional Networks, and Reliability, Reproducibility</td>
</tr>
<tr>
<td>Spectral features</td>
<td>f(ALFF)</td>
<td></td>
<td>Spontaneous BOLD Signal Fluctuations and Functional Networks, and Reliability, Reproducibility</td>
</tr>
<tr>
<td>CBF</td>
<td>Average biophysical model of perfusion weighted images</td>
<td>ATT</td>
<td>Arterial Spin Labeling and Cerebral Perfusion and Combined ASL/BOLD fMRI and Neurovascular Coupling</td>
</tr>
<tr>
<td>BOLD signal</td>
<td>Fitting a hemodynamic response to drug’s pharmacokinetic curve.</td>
<td>Pharmacological fMRI (Pharma-fMRI), Dose/Response in Anesthesiology, and Methods Validation and Calibration</td>
<td></td>
</tr>
</tbody>
</table>
After a relatively long period of development, PET/MR scanners have now reached the stage of commercial availability [Heiss, 2016], and are sold as whole-body, dedicated brain and pre-clinical (small animal) systems. The first immediate benefit of such systems is that they improve anatomical localization of PET anomalies in oncology [Bagade et al., 2015] and clinical studies in dementia and other neurodegenerative diseases [Barthel et al., 2015; Schutz et al., 2016] and epilepsy [Shin et al., 2015]. In the field of translational pharmacological research, the combination of simultaneous MRI and PET acquisitions allows for better interpretation of different resting-state fMRI metrics [Aiello et al., 2016], which is of course critical to the interpretation of pharma-fMRI. In one such study, Aiello et al. [2015] have provided evidence for a regionally specific correlation between regional glucose uptake (FDG-PET) and simultaneously measured REHO and fALFF. Their findings confirm the importance of considering spatial heterogeneity of the relations between metabolism and blood-flow-driven measures obtained from fMRI [Aiello et al., 2015]—a concern that requires more careful modeling and interpretation of pharma-RSfMRI studies [Khalili-Mahani et al., 2014]. Particularly, hybrid PET/fMRI will help better understand the coupling [Riedl et al., 2014; Soddu et al., 2016] and the decoupling [Di et al., 2012] of metabolic and connectivity metrics against the pathological background over which pharmacological interventions may be performed.

The second, and by far the most important impact of combined PET/MRI technologies on pharmacological...
interventions will come from combining different but highly complementary types of information gleaned during the exact same time frame from the two techniques. Such studies have only recently become feasible. For example, in a recently reported study hybrid PET/MRI has been used to assess receptor occupancy variations and BOLD variations using different 5-HT1a agonists, in order to evaluate whether it is possible to target different cellular pathways using molecules with similar receptor targeting-properties, but slightly different binding which will affect molecular/pharmacological responses [Vidal et al., 2016]. Hybrid PET/MRI will also be critical for advancing both kinetic modeling for PET, and by extension PK/PD modeling for fMRI. Both PET and PK/PD modeling depend on accurate assessment of the arterial input functions (AIF) for full quantification of tracer kinetics or pharmacokinetics. In PET studies, this is typically obtained from arterial blood sampling, an invasive, cumbersome and often inaccurate approach. To address this problem, Su et al. [2016] have developed and validated an image-derived AIF (IDAIF) estimation technique to simultaneously quantify brain hemodynamic parameters, by acquiring a TOF MRA in the same anatomical space as the PET data in order to assess image-derived time-activity curves in arterial regions of interest [Su et al., 2016].

Such interventions are, again, only beginning to be reported. However, by drawing on the strengths of fMRI (high spatial/temporal resolutions) and of PET (high sensitivity to even limited signal changes, access to a large variety of highly specific ligands), combined PET/MRI studies have the potential to bring pharmacological intervention studies to a new level of sophistication.

**CONCLUSIONS**

This survey provides compelling evidence for applicability of the pharma-RSfMRI method in studying neurochemistry. Animal studies corroborate the viability of these methods in pharmacological research, but the ultimate goal of PK/PD modeling hinges on further reliability and reproducibility tests, characterizing confounding factors that determine the interpretability of RSfMRI biomarkers and establishing meaningful effect size. This review illustrates the great degree of heterogeneity in data acquisition, experimental and analytical designs, statistical analysis and modeling of existing reports, and highlights the need for further research and development to create a standardized framework for data acquisition and analysis of pharmacological studies. We share recent concerns about validity and reliability of fMRI studies, and emphasize the fact that most existing statistical analyses methods are oblivious to nonstationarity of functional networks, and complex dynamics of regionally heterogeneous neurochemical modulation of the neuroimaging signals. We have provided a summary table of the basic and advanced options for design and execution of pharma-RSfMRI studies. To have these many options is itself a limitation in terms of what the optimum approach could be. However, the minimum requirements for such studies should include: (1) Placebo-controlled, repeated measures, and cross-over design; (2) multimodal data acquisition including data to characterize cerebral blood flow, and brain anatomy (myelin, and cerebrovascular architecture); (3) diligent monitoring of physiological pulses during the MRI acquisition as well as recording of somatosensory and awareness states; (4) studying the impact of preprocessing and noise-regression residuals on statistical inference tests; (5) permutation testing of a multivariate parameter space.

In conclusion, we emphasize the necessity of collaborative efforts in at least two areas:

- First, the community (including pharmaceutical industry) must invest into developing practical and methodological frameworks that promote and facilitate data-sharing and allow for meta- and mega-analyses of existing pharma-RSfMRI data. Such a framework will also enable the community to evaluate and optimize different preprocessing and modeling pipelines. Only within a standardized data-processing framework would it be possible to investigate the commonality and differences sensitivity of different biomarkers to different drug classes.

- Second, the community must adopt a set of standardized basic practices for data acquisition, which takes advantages of the state-of-the-art imaging technologies for acquiring multispectral and quantitative MRI data, as well as various metabolic, physiological and psychometric samples. A rich multimodal data (for different drug types) can be explored using multivariate and univariate analysis methods, to answer a range of questions about the effect size, specificity, reliability and, most importantly, interpretation of the biomarkers. It can also help us investigate between-subject variations in response to the same drug.

Collaborations between neuroimaging methodologists and clinical neuropharmacologists over such experiments will be mutually beneficial. To develop and validate non-invasive methods and biomarkers for studying drug effects on the brain will also open a window of opportunity to study the chemical underpinnings of healthy brain development and aging, with implications for clinical diagnostics and interventions.

**REFERENCES**


Dai W, Garcia D, de Bazelaire C, Alsop DC (2008): Continuous flow-driven inversion for arterial spin labeling using pulsed...


